

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

10X GENOMICS, INC. and PRESIDENT AND FELLOWS OF HARVARD COLLEGE,	)	
	)	
Plaintiffs,	)	C.A. No. 22-261-MFK
	)	
v.	)	JURY TRIAL DEMANDED
	)	
NANOSTRING TECHNOLOGIES, INC.,	)	OUTSIDE ATTORNEYS' EYES ONLY
	)	INFORMATION
Defendant.	)	
NANOSTRING TECHNOLOGIES, INC.,	)	
	)	
Counterclaim-Plaintiff,	)	
	)	
v.	)	
	)	
10X GENOMICS, INC.,	)	
	)	
Counterclaim-Defendant.	)	

NANOSTRING TECHNOLOGIES, INC.'S INITIAL INFRINGEMENT CONTENTIONS

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

Pursuant to Paragraph 7(c) of the Court's Scheduling Order (D.I. 55), Counterclaim-Plaintiff NanoString Technologies, Inc. ("NanoString"), hereby provide its initial infringement claim chart to Counterclaim-Defendant 10x Genomics, Inc. ("10x") as to U.S. Patent No. 11,377,689 ("689 Patent") with respect to the Accused Products which include all products, components, and services that are made, used, performed, offered to sell, sold, and/or imported into the United States by or on behalf of 10x in connection with 10x's Visium Spatial Gene Expression System ("Visium"). *See* Attachment A.

I. BACKGROUND

Discovery is in an early stage. NanoString will supplement its infringement contentions as discovery proceeds. These disclosures are based on the limited discovery that NanoString has been able to obtain to date. The structure and operation of the Accused Product is in significant part proprietary, has not yet been adequately disclosed by 10x, and is expected to be the subject of future discovery.

Further, 10x's technical document production is deficient in numerous substantial respects and not yet remedied. 10x has not produced any core technical documents in the present case or identified any documents produced in the matter of 10x Genomics, Inc. and Prognosys Biosciences, Inc. v. NanoString Technologies, Inc., Case No. 21-cv-653-MFK ("Prognosys Case") as core technical documents in the present case. NanoString continues to take discovery to identify and/or evaluate additional products or activities that are reasonably similar to those accused. These disclosures are without any concession, agreement, admission, or waiver of any ultimate determination of relevance, admissibility, or discoverability of any information for any purpose, and without waiver of any attorney-client, work product, or other privilege or immunity.

NanoString makes these disclosures, including the claim chart attached as Attachment A, based on information presently available from public sources and from 10x's production in the

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

Prognosys Case, without the benefit of full discovery or claim construction disclosures in the present case. NanoString reserves the right to supplement and/or amend these disclosures to the full extent consistent with the Court's rules and orders, for example, after receiving discovery from 10x, including the production of technical documents and testimony, or as appropriate in response to 10x's disclosures and contentions regarding claim scope or determination of other legal issues.

II. IDENTIFICATION OF THE ASSERTED CLAIMS

Pursuant to Paragraph 7(c) of the Court's Scheduling Order (D.I. 55), NanoString identifies the following Asserted Claims of the '689 Patent: Claims 1, 6, 8-12, 14-17, 21, 23-30.

III. CLAIM CHART FOR INFRINGEMENT OF THE ASSERTED CLAIMS

Attachment A is a claim chart showing examples of 10x's infringement of the '689 Patent identifying, based on information available to NanoString to date, specifically where each limitation of each asserted claim is found within or performed by exemplary Accused Products. The attachment may contain 10x's confidential material and is marked as such.

Several elements of the Asserted Claims may be satisfied by more than one feature, structure, process, or use of the Accused Products. The claim charts therefore may include alternative contentions and theories. For example, where multiple features are identified as corresponding to a particular claim element, the multiple features may be viewed as alternative or supplemental to one another. Further, NanoString's claim charts identify exemplary documentation for each limitation, and NanoString reserves all rights to supplement additional documentation as discovery proceeds. Moreover, NanoString asserts that the technical documents for various modalities (*e.g.*, analysis of fresh frozen or FFPE tissue samples, as well as the protein co-detection and targeted gene expression analysis that use the same method and, therefore, also infringe) are representative for purposes of the infringement contentions and may use such documents interchangeably.

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

Specifically, while the attached claim chart discloses representative infringement by Visium for Fresh Frozen and Visium for FFPE, other Visium products, including without limitations Visium Spatial Proteogenomics and Visium Spatial Gene Expression using the targeted panels, also infringe the Asserted Claims for the same exemplary reasons because these other Visium products are based on the same workflow as in Visium for Fresh Frozen and/or Visium for FFPE. *See, e.g.*, 10XN653-00021418; 10XN653-00021431; 10XN653-00021110 at 21110 (“The Visium Spatial Gene Expression Solution with immunofluorescence enhances these techniques, letting you combine immunofluorescence protein detection and unbiased, spatial gene expression in the same tissue section alongside histological analysis.”); *id.* (“The combined Visium Spatial Gene Expression with Immunofluorescence workflow makes it easy to implement spatial transcriptomics technology into standard methods of tissue sectioning and immunofluorescence staining.”); *id.* at Figure 1; 10XN653-00021462; 10XN653-00021248 at 21260 (“The Targeted Gene Expression product is a modular enrichment kit designed to enrich libraries for relevant genes, while decreasing sequencing requirements by up to 90%. ... This document outlines the protocol for generating Targeted Gene Expression libraries from Visium Spatial Gene Expression libraries that have been generated previously using the Visium Spatial Gene Expression Reagent Kits User Guide (Document CG000239, Rev D and onward).”).

In addition, the chart is submitted without prejudice to NanoString’s supplementation, amendment, or revision of these disclosures at an appropriate future date. NanoString expressly reserves the right to amend or supplement these disclosures for at least any of the following reasons, and as expressly permitted by the Delaware Default Standard for Discovery: 10x’s production of other technical documentation or testimony concerning any of the Accused Products and/or their components; the disclosure of 10x’s claim construction positions, invalidity

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

contentions, or non-infringement contentions or disclosures; any assertion by 10x that the modalities and/or cited documents are not in some way representative of the accused features; the Court's construction of any limitation of any Asserted Claim or any other legal determination of other issues; or for any other permissible reasons.

10x directly infringes the Asserted Claims of the '689 Patent through its own use of the Accused Products on behalf of its own scientists and researchers for various purposes, including, without limitation, research, development, sales, and support. NanoString reserves all rights to amend and supplement this disclosure as discovery proceeds. Moreover, 10x's Visium customers and users directly infringe the Asserted Claims of the '689 Patent by using the Accused Products in the manner described in 10x's product materials and as described in the attached claim chart. NanoString reserves all rights to amend and supplement this disclosure as discovery proceeds.

These disclosures provide examples of infringement that illustrate NanoString's infringement theories. However, the examples are non-limiting and are included to assist in understanding NanoString's infringement theories. For example, details regarding how the claims are implemented by and through the Accused Products may vary across instrumentalities in ways not material to the analysis of the Asserted Claims. The specific products selected for the most detailed discussions in the attached chart are, as explained in the chart itself and as further addressed in this document, to be understood as representative of other products with structures, operation, or other charted characteristics that do not differ from the charted products in ways material to NanoString's theories of infringement for the charted claims. NanoString reserves all rights to amend and supplement these disclosures as discovery proceeds and/or if 10x asserts that the available document is not representative for some purpose.

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

IV. INFRINGEMENT OF THE ASSERTED PATENT UNDER THE DOCTRINE OF EQUIVALENTS

The attached claim chart discloses the elements of the Asserted Claims that are believed to be literally present in 10x's technology and where NanoString contends—based on information available to NanoString today, including 10x's narrow contention of non-infringement—that a claim limitation is also met by elements of the Accused Products under the doctrine of equivalents. To the extent that NanoString contends a limitation is also met under the doctrine of equivalents, NanoString further contends that additional limitations of that claim and related claims including its dependent claims are also met under the doctrine of equivalents and for the same reasons. To date, 10x has not provided any detailed non-infringement contentions. NanoString reserves the right to assert infringement under the doctrine of equivalents if 10x timely discloses that it contends that one or more limitations are not literally present. NanoString reserves the right to further identify and describe its literal infringement and infringement under the doctrine of equivalents as further discovery is provided by 10x.

As to 10x's performance of the claimed methods as described in the attached chart, to the extent that any element of the any claim is practiced or alleged by 10x to be practiced by a party or entity other than 10x, NanoString may assert, and reserve the right to assert, that such other party or entity practices such element under the direction or control of 10x or otherwise in a manner that renders 10x responsible for the performance of the entirety of the Asserted Claims, pursuant to, *inter alia*, Section 271(a), and associated case law.

V. INDIRECT INFRINGEMENT OF THE ASSERTED PATENT

NanoString further asserts that 10x is liable for induced or contributory infringement pursuant to Sections 271(b) and 271(c) and associated case law. 10x is liable under 271(b) and

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

271(c) for direct infringement by its customers and end users of the Accused Products in performing the claimed methods with or through the Accused Products.

10x encourages its customers and other third parties to perform the claimed methods, for example, by providing and intending that third parties use the Accused Products in the manner instructed and encouraged in 10x's product documentation and training materials; purposefully and voluntarily placing the Accused Products in the stream of commerce with the expectation that they will be used by customers throughout the United States and in the District of Delaware in a manner that infringes the claimed methods; providing other components of the system that enable and/or make use of the Accused Products including; advertising the Accused Products through its own and third-party media platforms, including websites and webinars. *See, e.g.*, 10XN653-00021078–10XN653-00021486.

10x's actions further constitute contributory infringement. For example, 10x sells and offers to sell within the United States, and imports into the United States, and supplies or causes to be supplied from the United States, components that are used to practice the claimed methods, , knowing that such components are especially made or adapted to perform the claimed methods. When, for example, 10x sells and offers to sell the accused Visium products and services, 10x contributes to the infringement of others who use Visium products and services to perform the claimed methods. These components are not staple articles or commodities of commerce suitable for substantial non-infringing uses. 10x profits from the sale of the Accused Products to those users.

NanoString incorporates by reference the allegations in its Complaint and any amendments thereto, along with analysis in the attached initial claim chart with respect to 10x's indirect infringing activity from the date of Complaint. NanoString further expects 10x to produce

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

documents and information during the course of the discovery that will support NanoString's indirect infringement allegations.

VI. WILLFUL INFRINGEMENT

NanoString is informed and believes that 10x's infringement of the '689 Patent has been and continues to be willful as of July 11, 2022. *See* D.I. 43 ¶ 145. NanoString further reserves the right to amend its contentions based on on-going discovery to allege 10x's willful infringement prior to July 11, 2022.

OF COUNSEL:

Edward R. Reines (admitted *pro hac vice*)
Derek C. Walter (admitted *pro hac vice*)
Yiqun Zhang (admitted *pro hac vice*)
WEIL, GOTSHAL & MANGES LLP
201 Redwood Shores Parkway
Redwood Shores, CA 94065
Phone: (650) 802-3000
Fax: (650) 802-3100
edward.reines@weil.com
derek.walter@weil.com
amber.zhang@weil.com

Christopher Pepe (admitted *pro hac vice*)
Amanda Branch (admitted *pro hac vice*)
WEIL, GOTSHAL & MANGES LLP
2001 M Street, NW, Suite 600,
Washington, DC 20036
Phone: (202) 682-7000
Fax: (202) 857-0940
christopher.pepe@weil.com
amanda.branch@weil.com

Natalie C. Kennedy (admitted *pro hac vice*)
Yi Zhang (admitted *pro hac vice*)
WEIL, GOTSHAL & MANGES LLP
767 Fifth Avenue
New York, New York 10153-0119
Phone: (212) 310 8145
Fax: (212) 310 8007
natalie.kennedy@weil.com
yi.zhang@weil.com

Dated: November 23, 2022

Respectfully submitted,

FARNAN LLP

/s/ Brian E. Farnan

Brian E. Farnan (Bar No. 4089)
Michael J. Farnan (Bar No. 5165)
919 N. Market St., 12th Floor
Wilmington, DE 19801
(302) 777-0300
(302) 777-0301 (Fax)
bfarnan@farnanlaw.com
mfarnan@farnanlaw.com

*Attorneys for Defendant and Counterclaim-
Plaintiff Nanostring Technologies, Inc.*

Attachment A

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

Exemplary Infringement of U.S. Patent No. 11,377,689 (“the ’689 Patent”)

by use of 10X’s Visium Spatial Gene Expression System

This case is in its early stages. Fact discovery is ongoing, and the parties continue to search for and produce relevant documents. NanoString therefore reserves the right to amend these contentions based upon further investigation and on discovery materials. NanoString reserves the right to rely on expert testimony and/or analysis. For an identification of the Accused Products, *see* footnote 1. It should be understood that the below chart applies to all Accused Products.

the ’689 Patent	10X’s Visium ¹
1. A method for spatially detecting at least one target analyte in a first	To the extent that the preamble is found to be limiting, 10X’s Visium products perform a method for spatially detecting at least one target analyte in a first location and a second location of a tissue sample. For example:

¹ Visium Spatial Gene Expression System (“Visium”) are all products, components, and services that are made, used, performed, offered to sell, sold, and/or imported in the United States by or on behalf of 10x in connection with 10x’s Visium Spatial Gene Expression for Fresh Frozen, Visium Spatial Gene Expression for FFPE, Visium Spatial Gene Expression with protein co-detection (or Visium Spatial Proteogenomics). Visium include, for example and without limitation, Visium CytAssist, Visium Spatial Gene Expression slides, Visium Spatial Gene Expression reagents, and analysis and visualization software, Space Ranger and Loupe Browser, and Certified Service Providers (CSP), that are sold by 10x for use in 10x’s Visium for spatially detecting target biological molecules via sample imaging and delivery of probes. Without limitation as to the named products, components, and services, these include but are not limited to: Dual Index Kit TS Set A (1000251); Dual Index Kit TT Set A (1000215); Human Gene Signature Panel (1000258); Human Immunology Panel (1000259); Human Neuroscience Panel (1000277); Human Pan-Cancer Panel (1000260); Library Amplification Kit (1000249); Target Hybridization Kit (1000248); Visium Accessory Kit (1000194); Visium CytAssist Calibration Kit (1000458); Visium CytAssist Reagent Accessory Kit (1000499); Visium CytAssist Spatial Gene Expression for FFPE, Mouse Transcriptome, 6.5mm (1000522); Visium CytAssist Spatial Gene Expression for FFPE, Mouse Transcriptome, 11mm (1000523); Visium CytAssist Spatial Gene Expression for FFPE, Human Transcriptome, 6.5mm (1000520); Visium CytAssist Spatial Gene Expression for FFPE, Human Transcriptome, 11mm (1000521); Visium CytAssist Training Kit (1000459); Visium Spatial for FFPE Gene Expression Kit, Human Transcriptome (1000338); Visium Spatial for FFPE Gene Expression Kit, Mouse Transcriptome (1000339); Visium Spatial for FFPE Gene Expression Starter Kit, Human Transcriptome (1000334); Visium Spatial for FFPE Gene Expression Starter Kit, Mouse Transcriptome (1000335); Visium Spatial Gene Expression Slide & Reagents Kit (1000187); Visium Spatial Gene Expression Starter

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
location and a second location of a tissue sample comprising:	<i>See infra</i> claim analysis for Claims 1 and 16. “Visium Spatial Gene Expression is a next-generation molecular profiling solution for classifying tissue based on total mRNA. Map the whole transcriptome with morphological context in FFPE or fresh frozen tissues to discover novel insights into normal development, disease pathology, and clinical translational research.” 10XN653-00021418. “No need to select regions of interest—analyze the whole transcriptome from an entire section.” <i>Id.</i> Map the spatial gene expression of complex tissue samples with slides that utilize poly(A) capture and novel spatial barcoding technology for library preparation. ... Barcoded libraries are mapped back to a specific spot on the Capture Area. This gene expression data is subsequently layered over a high-resolution microscope image of the tissue section, making it possible to visualize the expression of any mRNA, or combination of mRNAs, within the morphology of the tissue in a spatially resolved manner. 10XN653-00021078 at 21079. <u>Visium for Fresh Frozen:</u> “The Visium Spatial Gene Expression Solution measures total mRNA in intact tissue sections and maps the location(s) where gene activity is occurring.” 10XN653-00060087 at 60101 (CG000239_Visium_Spatial_Gene_Expression_User_Guide_Rev_F at 15).

Kit (1000200); Visium Spatial Tissue Optimization Slide & Reagents Kit (1000193); Visium Tissue Section Test Slides, 4 Slide Pack (1000347); Custom Panel Designer; Loupe Browser; Space Ranger; Certified Service Providers.


OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
	Visium Spatial Gene Expression measures either the whole transcriptome or a defined set of transcripts in intact fresh frozen tissue sections and maps where gene activity is occurring. With whole transcriptome analysis, discover and reveal the spatial organization of cell types, states, and biomarkers. Focus on specific genes or pathways of interest with our pre-designed oncology, immunology, or neuroscience targeted gene panels. Combine with immunofluorescence for simultaneous visualization of protein and gene expression. 10XN653-00021098 at 21098 (10x_LIT059_ProductSheet_VisiumSpatialGeneExpression_Letter_digital at 1). A. Digital histology OR Immunofluorescence → Comprehensive, Spatial Gene Expression profile (3' DGE) B. H&E, Visium whole transcriptome (Total UMI scale: 20,000 to 80,000), Visium spot clusters, Cluster 4 mRNAs (Lamp5, Igfbp6, Tsp1, Egr1, Lmo4, Vip, Satb1, Egr1, Epcp, Irf5) <i>Id.</i> Fresh frozen tissue is sectioned, placed onto a library preparation slide, fixed, stained with either H&E or immunofluorescence, imaged, and permeabilized to release mRNA that binds to spatially barcoded capture probes, allowing for the capture of gene expression information. cDNA is synthesized from captured mRNA and then washed off the slide before sequencing library construction. Whole transcriptome or targeted gene expression libraries are sequenced and data can be analyzed and visualized using Space Ranger and Loupe Browser, our easy-to-use data analysis and visualization software. Loupe Browser


OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
	enables direct comparison of gene expression with histology or immunofluorescence protein data. <i>Id.</i> at 21099. <i>Id.</i> <u>FFPE:</u> “Visium Spatial Gene Expression for FFPE assays RNA levels by using probes against the whole transcriptome in intact formalin fixed paraffin embedded (FFPE) tissue sections and maps the location(s) where gene activity is occurring.” Ex. 1 (CG000407_VisiumSpatialGeneExpressionforFFPE_UserGuide_RevD) at 18. Visium Spatial Gene Expression for FFPE samples is a groundbreaking solution that complements traditional pathologist-led analysis. Spatially profile RNA expression for over 18,000 genes in human and mouse FFPE samples with high resolution across entire tissue sections. With whole transcriptome analysis and our specialized chemistry for FFPE tissue profiling, you can detect any gene in any pathway, resolve tissue heterogeneity, and reveal the spatial organization of cell types and cell states within a

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
	morphological context. Combine with immunofluorescence (IF) for simultaneous visualization of protein and gene expression. 10XN653-00021094 at 21094 (10x_LIT000128_PS_Spatial_biology_without_limits_Spatial_gene_expression_in_FFPE at 1).  The diagram illustrates the Visium spatial gene expression workflow. It begins with a tissue section on a slide, which is imaged with a microscope. The resulting data is visualized as a spatial map of gene expression, which can be used for biomarker discovery, clinical research, and understanding normal and diseased tissue. <i>Id.</i> An FFPE tissue section is placed onto a Visium gene expression slide and imaged for histological purposes (either H&E for morphological context or IF for protein co-detection). Each Capture Area on a Visium for FFPE slide has an array containing capture probes that bind to RNA. The probe pairs are extended to incorporate complements of the spatial barcodes, and sequencing libraries are prepared. The libraries are then sequenced and data visualized to determine which genes are expressed, and where, as well as in what quantity. <i>Id.</i> at 21095.

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
	 <i>Id.</i> To the extent Visium and related products are argued by Counterclaim-Defendant or found by the Court not to literally infringe certain limitations of the '689 Patent, infringement of such limitations can be found under the doctrine of equivalents.
a) contacting the tissue sample with a plurality of nucleic acid probes, wherein each of the nucleic acid probes comprise a target binding domain that binds to the at least one target analyte, wherein the tissue sample is treated to facilitate	10x's Visium performs a method comprising contacting the tissue sample with a plurality of nucleic acid probes, wherein each of the nucleic acid probes comprise a target binding domain that binds to the at least one target analyte, wherein the tissue sample is treated to facilitate binding of the nucleic acid probes to the target analyte. For example: <u>Visium for Fresh Frozen:</u> In the Visium for fresh frozen workflow, the tissue sample is contacted with a plurality of nucleic acid probes (<i>e.g.</i>, the primers in the capture areas of the Visium slides). Furthermore, each of the nucleic acid probes comprise a target binding domain (<i>e.g.</i>, the poly(dT) sequence) that binds to the at least one target analyte (<i>e.g.</i>, mRNAs).


OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
binding of the nucleic acid probes to the target analyte;	The Visium Spatial Gene Expression Solution measures total mRNA in intact tissue sections and maps the location(s) where gene activity is occurring. Each Visium Spatial or Gateway Gene Expression Slide contains Capture Areas with gene expression spots that include primers required for capture and priming of poly-adenylated mRNA. Tissue sections placed on these Capture Areas are fixed and stained, as described in Tissue Fixation & Staining Demonstrated Protocols – CG000160 or CG000312, permeabilized, and cellular mRNA is captured by the primers on the gene expression spots. All the cDNA generated from mRNA captured by primers on a specific spot share a common Spatial Barcode. Libraries are generated from the cDNA and sequenced and the Spatial Barcodes are used to associate the reads back to the tissue section images for spatial gene expression mapping. 10XN653-00060087 at 60101 (CG000239_Visium_Spatial_Gene_Expression_User_Guide_Rev_F at 15). The Visium Spatial Gene Expression Slide includes 4 Capture Areas (6.5 x 6.5 mm), each defined by a fiducial frame (fiducial frame + Capture Area is 8 x 8 mm). The Visium Gateway Gene Expression Slide includes 2 Capture Areas that are identical in size. The Capture Area has ~5,000 gene expression spots, each spot with primers that include: • Illumina TruSeq Read 1 (partial read 1 sequencing primer) • 16 nt Spatial Barcode (all primers in a specific spot share the same Spatial Barcode) • 12 nt unique molecular identifier (UMI) • 30 nt poly(dT) sequence (captures poly-adenylated mRNA for cDNA synthesis). <i>Id.</i>

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
	<i>Id.</i> The tissue sample is treated to facilitate binding of the nucleic acid probes to the target analyte. Specifically, the tissue sample is treated with enzyme and permeabilized under which a plurality of oligonucleotides are released from the tissue sample and captured by the primers on the spots of the Visium slides. “A Permeabilization Enzyme is used to permeabilize the fixed and stained tissue sections on the slide. The poly-adenylated mRNA released from the overlying cells is captured by the primers on the spots.” <i>Id.</i> at 60102.

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
	Permeabilization  Reactions on slide Capture Areas  The diagram illustrates the process of tissue permeabilization and the resulting cDNA synthesis on the slide. It shows a slide with capture areas and the reaction of mRNA with capture probes to form cDNA. The diagram includes labels for 'Slide', 'Read 1 Spatial UMI Poly(dT)VN', 'Barcode', and 'Tissue Permeabilization'. <i>Id.</i> The Visium Spatial Gene Expression Solution measures total mRNA in intact tissue sections and maps where that gene activity is occurring. Prior to library preparation, the Visium Spatial Tissue Optimization workflow allows the user to optimize permeabilization conditions for a tissue of interest. Tissue sections are placed onto corresponding Capture Areas on the Visium Spatial Tissue Optimization Slide. These sections are fixed and stained, as described in Tissue Fixation & Staining Demonstrated Protocols – CG000160 or CG000312, and then permeabilized for different times. mRNA released during permeabilization binds to capture probes on the slide. cDNA is generated using fluorescently labeled nucleotides to visualize synthesized cDNA. Finally, the tissue is enzymatically removed, leaving fluorescently labeled cDNA that may be visualized using fluorescence microscopy to select the optimal permeabilization time. At the successful completion of this protocol, users should proceed to the Visium Gene Spatial Gene Expression Protocol using the Visium Spatial Gene Expression Reagent Kits User Guide (CG000239). 10XN653-00021114 at 21125 (CG000238_VisiumSpatialTissueOptimizationUserGuide_RevD.pdf at 12).

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
	<u>Visium for FFPE:</u> In the Visium for FFPE workflow, the tissue sample is contacted with a plurality of nucleic acid probes. Furthermore, each of the nucleic acid probes comprise a target binding domain that binds to the at least one target analyte (<i>e.g.</i>, mRNAs). Visium Spatial Gene Expression for FFPE assays RNA levels by using probes against the whole transcriptome in intact formalin fixed paraffin embedded (FFPE) tissue sections and maps the location(s) where gene activity is occurring. Each Visium Spatial Gene Expression Slide contains Capture Areas with gene expression spots that include primers required to capture the probes. Tissue sections placed on these Capture Areas are deparaffinized, stained, and decrosslinked, as described in Deparaffinization & Staining Demonstrated Protocols – CG000409 or CG000410. Human or mouse whole transcriptome probe panels, consisting of a pair of specific probes for each targeted gene, are then added to the tissue. These probe pairs hybridize to their gene target and are then ligated to one another. The ligation products are released from the tissue upon RNase treatment and permeabilization. The ligated probe pairs bind with spatially barcoded oligonucleotides present on the Capture Area. All the probes captured by primers on a specific spot share a common Spatial Barcode. Libraries are generated from the probes and sequenced and the Spatial Barcodes are used to associate the reads back to the tissue section images for spatial mapping of gene expression. Ex. 1 (CG000407_VisiumSpatialGeneExpressionforFFPE_UserGuide_RevD) at 18. “Step 1 Probe Hybridization. The human or mouse whole transcriptome probe panel, consisting of a pair of specific probes for each targeted gene, is added to the deparaffinized, stained, and decrosslinked tissues. Together, probe pairs hybridize to their complementary target RNA.” <i>Id.</i> at 19.

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
	The diagram illustrates the Visium Spatial Gene Expression workflow. At the top, a circular inset shows a tissue sample with cells, and a microscope icon is shown to the right. Below this, a probe is shown with a 5' Read 2S (LHS) and a 5' Read 2S (RHS) region. The probe is hybridized to an mRNA target site, which is labeled 'mRNA Target Site' and has a 3' to 5' orientation. The probe hybridization step is indicated by a downward arrow labeled 'Probe Hybridization'. The final state shows the probe bound to the mRNA target site, with the 5' Read 2S (LHS) and 5' Read 2S (RHS) regions clearly visible. <i>Id.</i> The tissue sample is treated to facilitate binding of the nucleic acid probes to the target analyte. “FFPE tissue sections should be deparaffinized, stained, imaged, and decrosslinked before proceeding with Visium Spatial Gene Expression for FFPE.” <i>Id.</i> at 37. The Visium Spatial Gene Expression for FFPE is designed to measure mRNA in tissue sections derived from formalin fixed & paraffin embedded (FFPE) tissue samples and requires a Visium Spatial slide with intact tissue sections as input. This protocol outlines deparaffinization, Hematoxylin & Eosin (H&E) staining, imaging, and decrosslinking of tissue for use with 10x Genomics Visium Spatial Gene Expression for FFPE assay. Deparaffinized, stained, and decrosslinked tissue sections are inputs for the downstream Visium Spatial Gene Expression for FFPE workflow. 10XN653-00030665 at 30665 (CG000409_Demonstrated_Protocol_VisiumSpatialFFPE_Deparaffin_H&E_RevB.pdf at 1).


OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
	To the extent Visium and related products are argued by Counterclaim-Defendant or found by the Court not to literally infringe certain limitations of the '689 Patent, infringement of such limitations can be found under the doctrine of equivalents.
b) collecting the nucleic acid probes, or portions thereof, bound to the at least one target analyte in a first location of the tissue sample under conditions that release the nucleic acid probes, or portions thereof, from the first location of the tissue sample;	10X's Visium performs a method comprising collecting the nucleic acid probes, or portions thereof, bound to the at least one target analyte in a first location of the tissue sample under conditions that release the nucleic acid probes, or portions thereof, from the first location of the tissue sample. For example: <u>Visium for Fresh Frozen:</u> On the Visium Spatial Gene Expression slides, each Capture Area contains approximately 5,000 gene expression spots, each of which corresponds to a location of a tissue sample where target analyte is collected, processed and analyzed. Each spot contains the probes with the same spatial barcode. The Visium Spatial Gene Expression Slide includes 4 Capture Areas (6.5 x 6.5 mm), each defined by a fiducial frame (fiducial frame + Capture Area is 8 x 8 mm). The Visium Gateway Gene Expression Slide includes 2 Capture Areas that are identical in size. The Capture Area has ~5,000 gene expression spots, each spot with primers that include: • Illumina TruSeq Read 1 (partial read 1 sequencing primer) • 16 nt Spatial Barcode (all primers in a specific spot share the same Spatial Barcode) • 12 nt unique molecular identifier (UMI) • 30 nt poly(dT) sequence (captures poly-adenylated mRNA for cDNA synthesis). 10XN653-00060087 at 60101 (CG000239_Visium_Spatial_Gene_Expression_User_Guide_Rev_F at 15).

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
	<i>Id.</i> “Each gene expression spot includes primers with a unique Spatial Barcode.” <i>Id.</i> at 60105. Target analyte (<i>e.g.</i>, mRNAs) is released from the tissue sample and bound by the probes at discrete locations of the tissue sample on the Visium slides. This includes, for example, that a plurality of mRNAs from a first location of the tissue sample that overlays a first spot on a Visium slide are released and bound by the probes at this first spot . “A Permeabilization Enzyme is used to permeabilize the fixed and stained tissue sections on the slide. The poly-adenylated mRNA released from the overlying cells is captured by the primers on the spots.” <i>Id.</i> at 60102.


OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
	Permeabilization  Reactions on slide Capture Areas  <i>Id.</i> Further, in the Visium for Fresh Frozen workflow, probes bound to target analyte in discrete locations of the tissue sample are released and collected for further analysis. This includes, for example, probes bound to target analyte at a first location of the tissue sample are collected under conditions that release the probes from this first location. “This is followed by denaturation and transfer of the cDNA from each Capture Area to a corresponding tube for amplification and library construction.” <i>Id.</i> at 60103. <u>Visium for FFPE:</u> Human or mouse whole transcriptome probe panels, consisting of a pair of specific probes for each targeted gene, are then added to the tissue. These probe pairs hybridize to their gene target and are then ligated to one another. The ligation products are released from the tissue upon RNase treatment and permeabilization. The ligated probe pairs bind with spatially barcoded oligonucleotides present on the Capture Area. All the probes captured by primers on a specific spot share a common Spatial Barcode. Libraries are generated

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
	from the probes and sequenced and the Spatial Barcodes are used to associate the reads back to the tissue section images for spatial mapping of gene expression. Ex. 1 (CG000407_VisiumSpatialGeneExpressionforFFPE_UserGuide_RevD) at 18. On the Visium Spatial Gene Expression slides, each Capture Area contains approximately 5,000 gene expression spots, each of which corresponds to a location of a tissue sample where analyte is collected, processed and analyzed. The Visium Spatial Gene Expression Slide has 4 Capture Areas. Each Capture Area is 6.5 x 6.5 mm and defined by a fiducial frame (fiducial frame + Capture Area is 8 x 8 mm). The Capture Area has ~5,000 gene expression spots, each spot with primers that include: • Illumina TruSeq Read 1 (partial read 1 sequencing primer) • 16 nt Spatial Barcode (all primers in a specific spot share the same Spatial Barcode) • 12 nt unique molecular identifier (UMI) • 30 nt poly(dT) sequence (captures ligation product). <i>Id.</i> The tissue sample is subject to RNase treatment and permeabilization under which the nucleic acid probes bound to target analyte are released from the tissue sample and collected by the primers at discrete locations on the Visium slides. This includes, for example, that the probes from a first location of the tissue sample that overlays a first spot on a Visium slide are released and collected by the primers at this first spot . Step 1 Probe Hybridization. The human or mouse whole transcriptome probe panel, consisting of a pair of specific probes for each targeted gene, is added to the deparaffinized, stained, and decrosslinked tissues. Together, probe pairs hybridize to their complementary target RNA. Step 2 Probe Ligation. After hybridization, a ligase is added to seal the junction between the probe pairs that have hybridized to RNA, forming a ligation product.

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
	Step 3 Probe Release & Extension The single stranded ligation products are released from the tissue upon RNase treatment and permeabilization, and then captured on the Visium slides. <i>Id.</i> at 19-20.  The diagram illustrates the process of probe release and extension in 10X Visium. It shows a tissue section on a slide, followed by RNA digestion, probe release, and capture on a surface. The final product is a single-stranded ligation product (Read 1, Spatial Barcode, UMI, Poly(dT)VN) attached to a slide, with a Read 2S 5' end. <i>Id.</i>

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
	To the extent Visium and related products are argued by Counterclaim-Defendant or found by the Court not to literally infringe certain limitations of the '689 Patent, infringement of such limitations can be found under the doctrine of equivalents.
c) collecting the nucleic acid probes, or portions thereof, bound to the at least one target analyte in a second location of the tissue sample under conditions that release the nucleic acid probes, or portions thereof, from the second location of the tissue sample;	10X's Visium performs a method comprising collecting the nucleic acid probes, or portions thereof, bound to the at least one target analyte in a second location of the tissue sample under conditions that release the nucleic acid probes, or portions thereof, from the second location of the tissue sample. For example: <i>See supra</i> analysis for Claim 1(b). Reagents are added to and reactions are performed on approximately 5000 distinct locations (gene expression spots) simultaneously. This includes, for example, that nucleic acid probes, or portions thereof, bound to the at least one target analyte in a second location of the tissue sample that overlays a second spot on a Visium slide are released and collected by the primers at this second spot. To the extent Visium and related products are argued by Counterclaim-Defendant or found by the Court not to literally infringe certain limitations of the '689 Patent, infringement of such limitations can be found under the doctrine of equivalents.
d) performing an extension reaction that incorporates at least one nucleic acid sequence that identifies the first location of the tissue sample into each of the nucleic acid probes, or portions thereof, collected in step (b), thereby forming a first plurality of extension	10x's Visium performs an extension reaction that incorporates at least one nucleic acid sequence that identifies the first location of the tissue sample into each of the nucleic acid probes, or portions thereof, collected in step (b), thereby forming a first plurality of extension products that comprise the nucleic acid probes, or portions thereof, collected in step (b) and the at least one nucleic acid sequence that identifies the first location of the tissue sample. For example: <i>See supra</i> analysis for claim 1(b). <u>Visium for Fresh Frozen:</u> Reagents are added to and reactions are performed on approximately 5000 distinct locations (gene expression spots) simultaneously. This includes, for example, that a plurality of spatially barcoded, full-

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
products that comprise the nucleic acid probes, or portions thereof, collected in step (b) and the at least one nucleic acid sequence that identifies the first location of the tissue sample;	length cDNAs (for fresh frozen) are formed by performing an extension reaction that incorporates at least one nucleic acid sequences that identifies the first location of the tissue sample (<i>e.g.</i>, the sequences that include spatial barcode) into each of the nucleic acid probes, or portions thereof, collected in step (b). Step 1 Permeabilization & Reverse Transcription. ... RT Master Mix containing reverse transcription reagents is added to the permeabilized tissue sections. Incubation with the reagents produces spatially barcoded, full-length cDNA from poly-adenylated mRNA on the slide. Step 2 Second Strand Synthesis & Denaturation. Second Strand Mix is added to the tissue sections on the slide to initiate second strand synthesis. This is followed by denaturation and transfer of the cDNA from each Capture Area to a corresponding tube for amplification and library construction. 10XN653-00060087 at 60102 (CG000239_Visium_Spatial_Gene_Expression_User_Guide_Rev_F at 16).

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
	Reactions on slide Capture Areas The diagram illustrates the seven-step process for single-cell RNA sequencing on a slide: Tissue Permeabilization: A tissue section is placed on a slide with a capture area containing a Read 1 Spatial UMI Barcode (green) and a Poly(dT)VN sequence (blue). The tissue is permeabilized to allow mRNA to pass through. Reverse Transcription: The mRNA is reverse transcribed into a cDNA-mRNA hybrid using a reverse transcriptase and a poly(dT) primer. Template Switch Oligo Priming: A Template Switch Oligo (TSO, green) binds to the poly(dT) sequence on the cDNA-mRNA hybrid. Transcript Extension: The TSO is extended by the reverse transcriptase, creating a second strand of cDNA. Second Strand Synthesis Priming: A Second Strand Primer (green) binds to the TSO. Second Strand Synthesis: The second strand of cDNA is synthesized using the Second Strand Primer and a DNA polymerase. Denaturation: The final product is a double-stranded cDNA molecule, ready for sequencing. <i>Id.</i> “Each gene expression spot includes primers with a unique Spatial Barcode.” <i>Id.</i> at 60105.

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
	The extension products—spatially barcoded, full-length cDNAs—comprise the nucleic acid probes, or portions thereof, collected in step (b) and the at least one nucleic acid sequence that identifies the first location of the tissue sample. <i>Id.</i> at 60102. <u>Visium for FFPE:</u> Reagents are added to and reactions are performed on approximately 5000 distinct locations (gene expression spots) simultaneously. This includes, for example, that a plurality of spatially barcoded, ligated probe products are formed by performing an extension reaction that incorporates at least one nucleic acid sequence that identifies the first location of the tissue sample into each of the nucleic acid probes, or portions thereof, collected in step (b). “Step 3 Probe Release & Extension. ... Once ligation products are captured, probes are extended by the addition of UMI, Spatial Barcode and partial Read 1. This generates spatially barcoded, ligated probe products, which can then be carried forward for library preparation.” Ex. 1 (CG000407_VisiumSpatialGeneExpressionforFFPE_UserGuide_RevD) at 20.

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
	The diagram illustrates the 10X Visium process in three stages. Stage 1: A 'Slide' is shown with a probe attached. The probe has a 'Read 1' (black), a 'Spatial Barcode' (green), a 'UMI' (orange), a 'Poly(dT)VN' (blue), and a '3' AAAAAAAAAA' (yellow) sequence. A 'Read 2S 5'' (purple) is also shown. Stage 2: 'Probe Extension' is indicated by a downward arrow. The probe is now extended, showing a 'Read 1' (black), a 'Spatial Barcode' (green), a 'UMI' (orange), a 'Poly A' (blue), and a 'Ligated Probe Insert' (yellow). Stage 3: 'Denaturation of Extended Probe & Probe Elution' is indicated by a downward arrow. The probe is now detached from the slide, showing a 'Read 1' (black), a 'Spatial Barcode' (green), a 'UMI' (orange), a 'Poly A' (blue), and a 'Ligated Probe Insert' (yellow). The 'Read 2S' (black) is also shown. <i>Id.</i> “Each gene expression spot includes primers with a unique Spatial Barcode.” <i>Id.</i> at 23. The extension products—spatially barcoded, ligated probe products—comprise the nucleic acid probes, or portions thereof, collected in step (b) and the at least one nucleic acid sequence that identifies the first location of the tissue sample. The diagram shows the final ligated probe product. It consists of a 'Read 1' (black), a 'Spatial Barcode' (green), a 'UMI' (orange), a 'Poly A' (blue), and a 'Ligated Probe Insert' (yellow). The 'Read 2S' (black) is also shown. The 'Spatial Barcode' and 'UMI' are highlighted with red boxes. <i>Id.</i> at 20 (annotated).

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
	To the extent Visium and related products are argued by Counterclaim-Defendant or found by the Court not to literally infringe certain limitations of the '689 Patent, infringement of such limitations can be found under the doctrine of equivalents.
e) performing an extension reaction that incorporates at least one nucleic acid sequence that identifies the second location of the tissue sample into each of the nucleic acid probes, or portions thereof, collected in step (c), thereby forming a second plurality extension products that comprise the nucleic acid probes, or portions thereof, collected in step (c) and the at least one nucleic acid sequence that identifies the second location of the tissue sample; and	10x's Visium performs a method comprising an extension reaction that incorporates at least one nucleic acid sequence that identifies the second location of the tissue sample into each of the nucleic acid probes, or portions thereof, collected in step (c), thereby forming a second plurality extension products that comprise the nucleic acid probes, or portions thereof, collected in step (c) and the at least one nucleic acid sequence that identifies the second location of the tissue sample. For example: <i>See supra</i> analysis for claims 1(b)-(d). Reagents are added to and reactions are performed on approximately 5000 distinct locations (gene expression spots) simultaneously. This includes, for example, that a plurality of that a plurality of spatially barcoded, full-length cDNAs (for fresh frozen) or spatially barcoded, ligated probe products (for FFPE) are formed by performing an extension reaction that incorporates at least one nucleic acid sequences that identifies the second location of the tissue sample (<i>e.g.</i>, the sequences that include spatial barcode) into each of the nucleic acid probes, or portions thereof, collected in step (c). To the extent Visium and related products are argued by Counterclaim-Defendant or found by the Court not to literally infringe certain limitations of the '689 Patent, infringement of such limitations can be found under the doctrine of equivalents.
f) identifying the first plurality of extension products and the second plurality of extension products by sequencing the first plurality of extension products and the second plurality of	10x's Visium performs identifying the first plurality of extension products and the second plurality of extension products by sequencing the first plurality of extension products and the second plurality of extension products, thereby spatially detecting the at least one target analyte in the first location of the tissue sample and the second location of the tissue sample. For example: <i>See supra</i> analysis for claim 1(a).

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
extension products, thereby spatially detecting the at least one target analyte in the first location of the tissue sample and the second location of the tissue sample.	<u>Visium for Fresh-Frozen:</u> “All the cDNA generated from mRNA captured by primers on a specific spot share a common Spatial Barcode. Libraries are generated from the cDNA and sequenced and the Spatial Barcodes are used to associate the reads back to the tissue section images for spatial gene expression mapping.” 10XN653-00060087 at 60101 (CG000239_Visium_Spatial_Gene_Expression_User_Guide_Rev_F at 15). Step 4 Visium Spatial Gene Expression Library Construction. Enzymatic fragmentation and size selection are used to optimize the cDNA amplicon size. P5, P7, i7 and i5 sample indexes, and TruSeq Read 2 (read 2 primer sequence) are added via End Repair, A-tailing, Adaptor Ligation, and PCR. The final libraries contain the P5 and P7 primers used in Illumina amplification. Step 5 Sequencing. A Visium Spatial Gene Expression library comprises standard Illumina paired-end constructs which begin and end with P5 and P7. The 16 bp Spatial Barcode and 12 bp UMI are encoded in Read 1, while Read 2 is used to sequence the cDNA fragment. i7 and i5 sample index sequences are incorporated. TruSeq Read 1 and TruSeq Read 2 are standard Illumina sequencing primer sites used in paired-end sequencing. <i>Id.</i> at 60103. <i>Id.</i> Visium Spatial Gene Expression libraries comprise standard Illumina paired-end constructs that are flanked with P5/P7, necessary for binding to the Illumina flow cell. TruSeq Read 1 is used for priming and sequencing the 16 bp Spatial Barcode and 12 bp

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
	UMI, and TruSeq Read 2 is used for priming and sequencing the cDNA insert. The two 10 bp sample indexes are sequenced in the i5 and i7 read respectively. <i>Id.</i> at 60145. “Sequencing Depth/spot: Minimum 50,000 read pairs per tissue covered spot on Capture Area” <i>Id.</i> <u>Visium for FFPE:</u> “All the probes captured by primers on a specific spot share a common Spatial Barcode. Libraries are generated from the probes and sequenced and the Spatial Barcodes are used to associate the reads back to the tissue section images for spatial mapping of gene expression.” Ex. 1 (CG000407_VisiumSpatialGeneExpressionforFFPE_UserGuide_RevD) at 18. Step 4 Visium Spatial Gene Expression - FFPE Library Construction. The spatially barcoded, ligated probe products are released from the slide and harvested for qPCR to determine Sample Index PCR cycle number. The products then undergo indexing via Sample Index PCR. This, in turn, generates final library molecules that are cleaned up by SPRIselect, assessed on a bioanalyzer or a similar instrument, quantified, and then sequenced. Step 5 Sequencing. A Visium Spatial Gene Expression – FFPE library comprises standard Illumina paired-end constructs which begin and end with P5 and P7. The 16 bp Spatial Barcode and 12 bp UMI are encoded in Read 1, while Small RNA Read 2 (Read 2S) is used to sequence the ligated probe insert. <i>Id.</i> at 21.


OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
	<i>Id.</i> FFPE libraries comprise standard Illumina paired-end constructs which begin with P5 and end with P7. 16 bp Spatial Barcodes are encoded at the start of TruSeq Read 1, while i7 and i5 sample index sequences are incorporated as the index read. TruSeq Read 1 and Small RNA Read 2 (Read 2S) are standard Illumina sequencing primer sites used in paired-end sequencing. TruSeq Read 1 is used to sequence 16 bp Spatial Barcode and 12 bp UMI. Small RNA Read 2 (Read 2S) is used to sequence the Ligated Probe Insert. <i>Id.</i> at 60. “Sequencing Depth/spot: Minimum 25,000 read pairs per tissue covered spot on Capture Area” <i>Id.</i> To the extent Visium and related products are argued by Counterclaim-Defendant or found by the Court not to literally infringe certain limitations of the '689 Patent, infringement of such limitations can be found under the doctrine of equivalents.
3. The method of claim 1, wherein the tissue sample is immobilized onto a microscope slide.	10x's Visium performs the method wherein the tissue sample is immobilized onto a microscope slide. For example: <i>See supra</i> analysis for Claim 1. In Visium workflow, tissue samples are immobilized onto Visium slides. The Visium slides are microscope slides.

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
	Image Capture Guidelines: The 8 mm x 8 mm area that includes the fiducial frame and the Capture Area with the tissue section should be represented by $\geq 2,000 \times 2,000$ pixel portion of the image. When setting the microscope for imaging individual Capture Area, the imaging area should be $\sim 1\text{-}2$ mm beyond the fiducial frame for optimal imaging alignment. Minimize imaging of any adjacent CaptureArea/s when taking images of a specific Capture Area with a tissue section. 10XN653-00060087 at 60097 (CG000239_Visium_Spatial_Gene_Expression_User_Guide_Rev_F at 11); Ex. 1 (CG000407_VisiumSpatialGeneExpressionforFFPE_UserGuide_RevD) at 14. <u>Visium for Fresh-Frozen:</u> The Visium Spatial Gene Expression Solution measures total mRNA in intact tissue sections and maps the location(s) where gene activity is occurring. Each Visium Spatial or Gateway Gene Expression Slide contains Capture Areas with gene expression spots that include primers required for capture and priming of poly-adenylated mRNA. Tissue sections placed on these Capture Areas are fixed and stained, as described in Tissue Fixation & Staining Demonstrated Protocols – CG000160 or CG000312, permeabilized, and cellular mRNA is captured by the primers on the gene expression spots. 10XN653-00060087 at 60101 (CG000239_Visium_Spatial_Gene_Expression_User_Guide_Rev_F at 15). Cryosectioning OCT embedded tissue blocks are removed from the -80°C storage and cryosectioned in a cryostat to generate appropriately sized sections for Visium Spatial slides while keeping the samples frozen. Section Placement Tissue sections are placed within the frames of Capture Areas on Visium Spatial slides. Only one section should be placed within each Capture Area. 10XN653-00026997 at 27006 (CG000240_Demonstrated_Protocol_VisiumSpatialProtocols_TissuePreparationGuide_RevD at 10).

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
	 The diagram illustrates the workflow for 10X's Visium technology. It begins with a red tissue sample in a container. An arrow labeled "Cryosectioning" points to a cryostat machine. Another arrow labeled "Section Placement" points to three different slide types: Visium Gateway Gene Expression Slide, Visium Spatial Gene Expression Slide, and Visium Spatial Tissue Optimization Slide. <i>Id.</i>



OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
	<u>Visium for FFPE:</u> Visium Spatial Gene Expression for FFPE assays RNA levels by using probes against the whole transcriptome in intact formalin fixed paraffin embedded (FFPE) tissue sections and maps the location(s) where gene activity is occurring. Each Visium Spatial Gene Expression Slide contains Capture Areas with gene expression spots that include primers required to capture the probes. Tissue sections placed on these Capture Areas are deparaffinized, stained, and decrosslinked, as described in Deparaffinization & Staining Demonstrated Protocols – CG000409 or CG000410. Ex. 1 (CG000407_VisiumSpatialGeneExpressionforFFPE_UserGuide_RevD) at 18. Sectioning The tissue block with exposed tissue is trimmed or scored to make it compatible in size to the Capture Areas on Visium slides. The tissue block is then sectioned by a microtome to generate appropriately sized sections for Visium slides. Section Placement Sections are collected in a water bath and are allowed to float on the water surface until they are flat and free from wrinkles and folds. The optimal floating time depends upon the specific tissue type and should be empirically determined when working with new tissue types. Expanded sections are then placed within the frames of Capture Areas on Visium Spatial slides. 10XN653-00021375 at 21383 (CG000408_Demonstrated_Protocol_VisiumSpatialProtocolsFFPE_TissuePreparationGuide_RevA at 9).

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
	FFPE Tissue Block ↓ Expose the Tissue ↓ Assess RNA Quality ↓ Section the Block ↓ Place Sections on Visium Spatial Slides ↓  Visium Spatial Gene Expression Slide <i>Id.</i>

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
	To the extent Visium and related products are argued by Counterclaim-Defendant or found by the Court not to literally infringe certain limitations of the '689 Patent, infringement of such limitations can be found under the doctrine of equivalents.
4. The method of claim 3, wherein the microscope slide comprises a plurality of primers immobilized on the microscope slide.	10's Visium performs the method wherein the microscope slide comprises a plurality of primers immobilized on the microscope slide. For example: <i>See supra</i> analysis for Claim 3. <u>Visium for Fresh-Frozen:</u>  10XN653-00060087 at 60155 (CG000239_Visium_Spatial_Gene_Expression_User_Guide_Rev_F at 69). <u>Visium for FFPE:</u>  Ex. 1 (CG000407_VisiumSpatialGeneExpressionforFFPE_UserGuide_RevD) at 71.

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
	To the extent Visium and related products are argued by Counterclaim-Defendant or found by the Court not to literally infringe certain limitations of the '689 Patent, infringement of such limitations can be found under the doctrine of equivalents.
5. The method of claim 4, wherein the plurality of primers is immobilized on the microscope slide at their 5' ends.	10x's Visium performs the method wherein the plurality of primers is immobilized on the microscope slide at their 5' ends. For example: <i>See supra</i> analysis for Claim 4. To the extent Visium and related products are argued by Counterclaim-Defendant or found by the Court not to literally infringe certain limitations of the '689 Patent, infringement of such limitations can be found under the doctrine of equivalents.
6. The method of claim 5, wherein each of step (d) and step (e) comprise performing a solid-phase amplification reaction, wherein the solid-phase amplification reaction is carried out on the microscope slide using the plurality of primers immobilized on the microscope slide.	10x's Visium performs the method wherein each of step (d) and step (e) comprise performing a solid-phase amplification reaction, wherein the solid-phase amplification reaction is carried out on the microscope slide using the plurality of primers immobilized on the microscope slide. For example: <i>See supra</i> analysis for Claims 1(d), 1(e) and 5. <u>Visium for Fresh-Frozen:</u> "Second Strand Mix is added to the tissue sections on the slide to initiate second strand synthesis. This is followed by denaturation and transfer of the cDNA from each Capture Area to a corresponding tube for amplification and library construction." 10XN653-00060087 at 60155 (CG000239_Visium_Spatial_Gene_Expression_User_Guide_Rev_F at 17).



OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
	Slide 3' AAAAAA rGrGrG C C C Second Strand Synthesis Priming Second Strand Primer Second Strand Synthesis <i>Id.</i> Visium for FFPE: “Once ligation products are captured, probes are extended by the addition of UMI, Spatial Barcode and partial Read 1. This generates spatially barcoded, ligated probe products, which can then be carried forward for library preparation.” Ex. 1 (CG000407_VisiumSpatialGeneExpressionforFFPE_UserGuide_RevD) at 20. Slide Read 1 Spatial Barcode UMI Poly(dT)VN 3' AAAAAA Read 2S 5' Probe Extension Read 2S 5' <i>Id.</i>

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
	To the extent Visium and related products are argued by Counterclaim-Defendant or found by the Court not to literally infringe certain limitations of the '689 Patent, infringement of such limitations can be found under the doctrine of equivalents.
8. The method of claim 1, further comprising amplifying a library using the first plurality of extension products and the second plurality of extension products as templates.	10x's Visium performs the method which further comprises amplifying a library using the first plurality of extension products and the second plurality of extension products as templates. For example: <i>See supra</i> analysis for Claim 1. <u>Visium for Fresh-Frozen:</u> Step 3 cDNA Amplification & QC. After transfer of cDNA from the slide, spatially barcoded, full-length cDNA is amplified via PCR to generate sufficient mass for library construction. Step 4 Visium Spatial Gene Expression Library Construction. Enzymatic fragmentation and size selection are used to optimize the cDNA amplicon size. P5, P7, i7 and i5 sample indexes, and TruSeq Read 2 (read 2 primer sequence) are added via End Repair, A-tailing, Adaptor Ligation, and PCR. The final libraries contain the P5 and P7 primers used in Illumina amplification. 10XN653-00060087 at 60102-3 (CG000239_Visium_Spatial_Gene_Expression_User_Guide_Rev_F at 16-17). The diagram illustrates the cDNA amplification process. It shows a single cDNA molecule with a spatial barcode (green), UMI (orange), and poly(dT)VN (blue) being amplified into multiple identical copies. The diagram is labeled 'cDNA amplification' and includes a legend for 'Spatial' (green), 'Barcode' (orange), 'UMI' (blue), 'Poly(dT)VN' (blue), and 'TSO' (green). <i>Id.</i> at 60102.

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
	Protocol Step 3.2 – cDNA Amplification cDNA Primers PN-2000089 Forward Primer:  Partial Read 1 5'-CTACACGACGCTCTCCGATCT-3' Reverse Primer:  Partial TSO 5'-AAGCAGTGGTATCAACGCAGAG-3' Amplification Products  <i>Id.</i> at 60155. <u>Visium for FFPE:</u> Step 4 Visium Spatial Gene Expression - FFPE Library Construction. The spatially barcoded, ligated probe products are released from the slide and harvested for qPCR to determine Sample Index PCR cycle number. The products then undergo indexing via Sample Index PCR. This, in turn, generates final library molecules that are cleaned up by SPRIselect, assessed on a bioanalyzer or a similar instrument, quantified, and then sequenced. Ex. 1 (CG000407_VisiumSpatialGeneExpressionforFFPE_UserGuide_RevD) at 21.  <i>Id.</i>

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
	To the extent Visium and related products are argued by Counterclaim-Defendant or found by the Court not to literally infringe certain limitations of the '689 Patent, infringement of such limitations can be found under the doctrine of equivalents.
9. The method of claim 1, wherein the at least one nucleic acid sequence that identifies the first location of the tissue sample comprises at least one unique molecular identifier.	10x's Visium performs the method wherein the at least one nucleic acid sequence that identifies the first location of the tissue sample comprises at least one unique molecular identifier. For example: <i>See supra</i> analysis for Claim 1. <u>Visium for Fresh-Frozen:</u> The Capture Area has ~5,000 gene expression spots, each spot with primers that include: • Illumina TruSeq Read 1 (partial read 1 sequencing primer) • 16 nt Spatial Barcode (all primers in a specific spot share the same Spatial Barcode) • 12 nt unique molecular identifier (UMI) • 30 nt poly(dT) sequence (captures poly-adenylated mRNA for cDNA synthesis). 10XN653-00060087 at 60101 (CG000239_Visium_Spatial_Gene_Expression_User_Guide_Rev_F at 15). <u>Visium for FFPE:</u> The Capture Area has ~5,000 gene expression spots, each spot with primers that include: • Illumina TruSeq Read 1 (partial read 1 sequencing primer) • 16 nt Spatial Barcode (all primers in a specific spot share the same Spatial Barcode) • 12 nt unique molecular identifier (UMI) • 30 nt poly(dT) sequence (captures ligation product). Ex. 1 (CG000407_VisiumSpatialGeneExpressionforFFPE_UserGuide_RevD) at 18.

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
	To the extent Visium and related products are argued by Counterclaim-Defendant or found by the Court not to literally infringe certain limitations of the '689 Patent, infringement of such limitations can be found under the doctrine of equivalents.
10. The method of claim 1, wherein the at least one nucleic acid sequence that identifies the second location of the tissue sample comprises at least one unique molecular identifier.	10x's Visium performs the method wherein the at least one nucleic acid sequence that identifies the second location of the tissue sample comprises at least one unique molecular identifier. For example: <i>See supra</i> analysis for Claims 1 and 9. To the extent Visium and related products are argued by Counterclaim-Defendant or found by the Court not to literally infringe certain limitations of the '689 Patent, infringement of such limitations can be found under the doctrine of equivalents.
11. The method of claim 1, wherein the at least one nucleic acid sequence that identifies the first location of the tissue sample comprises at least one amplification primer binding site.	10x's Visium performs the method wherein the at least one nucleic acid sequence that identifies the first location of the tissue sample comprises at least one amplification primer binding site. For example: <i>See supra</i> analysis for Claims 1 and 9. <u>Visium for Fresh-Frozen:</u> In Visium workflow for fresh-frozen, the DNA products comprise at least the TruSeq Read 1 and TSO amplification primer binding sites. The nucleic acid sequence comprises at least the TruSeq Read 1 amplification primer binding site. “Step 3 cDNA Amplification & QC. After transfer of cDNA from the slide, spatially barcoded, full-length cDNA is amplified via PCR to generate sufficient mass for library construction.” 10XN653-00060087 at 60102 (CG000239_Visium_Spatial_Gene_Expression_User_Guide_Rev_F at 16).

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
	<i>Id.</i> The DNA products undergo further library construction where TruSeq Read 1 and Read 2 amplification primer bindings sites are used. After the library construction, the DNA products further comprise the P5 and P7 primers used in Illumina amplification. The nucleic acid sequence comprises at least the P5 amplification primer binding site. Step 4 Visium Spatial Gene Expression Library Construction. Enzymatic fragmentation and size selection are used to optimize the cDNA amplicon size. P5, P7, i7 and i5 sample indexes, and TruSeq Read 2 (read 2 primer sequence) are added via End Repair, A-tailing, Adaptor Ligation, and PCR. The final libraries contain the P5 and P7 primers used in Illumina amplification. <i>Id.</i> at 18.

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
	The diagram illustrates the 'Amplified cDNA processing (dual index)' workflow. It starts with a cDNA molecule containing a 'Spatial Barcode' (green), a 'UMI' (orange), and a 'Poly(dT)VN' sequence (blue). This is followed by 'Enzymatic Fragmentation' and 'End Repair, A-tailing, Ligation' to create 'Read 2'. After 'Cleanup & Priming', the molecule is ready for 'Sample Index PCR'. The final product is a library molecule with 'P5' and 'Sample Index (i5)' primers on one end, and 'Read 1', 'Spatial Barcode', 'UMI', 'Poly(dT)VN', and 'Sample P7 Index (i7)' on the other. <i>Id.</i> at 18. <u>Visium for FFPE:</u> In Visium workflow for FFPE, the DNA products comprise at least the TruSeq Read 1 and Read 2s amplification primer binding sites. The nucleic acid sequence comprises at least the TruSeq Read 1 amplification primer binding site. After the library construction, the DNA products further comprise the P5 and P7 primers used for Illumina amplification. The nucleic acid sequence comprises at least the P5 amplification primer binding site. Step 4 Visium Spatial Gene Expression - FFPE Library Construction. The spatially barcoded, ligated probe products are released from the slide and harvested for qPCR to determine Sample Index PCR cycle number. The products then undergo indexing via Sample Index PCR. This, in turn, generates final library molecules that are cleaned up by SPRIselect, assessed on a bioanalyzer or a similar instrument, quantified, and then sequenced. Ex. 1 (CG000407_VisiumSpatialGeneExpressionforFFPE_UserGuide_RevD) at 21.

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
	The diagram illustrates the 10X Visium sequencing process. It shows a DNA construct with various regions: P5 (blue), i5 (grey), Read 1 (black), a Ligated Probe Insert (yellow), Read 2S (black), i7 (grey), and P7 (yellow). An arrow labeled 'Sample Index PCR' points to the bottom part of the diagram, which shows the same construct after PCR, with the addition of a Spatial Barcode (green) and UMI (orange) between Read 1 and the Ligated Probe Insert. <i>Id.</i> FFPE libraries comprise standard Illumina paired-end constructs which begin with P5 and end with P7. 16 bp Spatial Barcodes are encoded at the start of TruSeq Read 1, while i7 and i5 sample index sequences are incorporated as the index read. TruSeq Read 1 and Small RNA Read 2 (Read 2s) are standard Illumina sequencing primer sites used in paired-end sequencing. TruSeq Read 1 is used to sequence 16 bp Spatial Barcode and 12 bp UMI. Small RNA Read 2 (Read 2S) is used to sequence the Ligated Probe Insert. Sequencing these libraries produces a standard Illumina BCL data output folder. <i>Id.</i> at 60. To the extent Visium and related products are argued by Counterclaim-Defendant or found by the Court not to literally infringe certain limitations of the '689 Patent, infringement of such limitations can be found under the doctrine of equivalents.
12. The method of claim 1, wherein the at least one nucleic acid sequence that identifies the second	10x's Visium performs the method where the at least one nucleic acid sequence that identifies the second location of the tissue sample comprises at least one amplification primer binding site. For example: <i>See supra</i> analysis for Claims 1, 9 and 11.

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
location of the tissue sample comprises at least one amplification primer binding site.	To the extent Visium and related products are argued by Counterclaim-Defendant or found by the Court not to literally infringe certain limitations of the '689 Patent, infringement of such limitations can be found under the doctrine of equivalents.
14. The method of claim 1, wherein steps (b) and (c) are performed simultaneously.	10x's Visium performs steps (b) and (c) of claim 1 simultaneously. For example: <i>See supra</i> analysis for Claim 1. Each step of the Visium workflow takes place across the whole tissue sample which covers the approximately 5,000 gene expression spots (<i>e.g.</i>, locations). "Always cover the tissue section completely when adding reagents to the well. A gentle tap may help spread the reagent more evenly." 10XN653-00060087 at 60111 (CG000239_Visium_Spatial_Gene_Expression_User_Guide_Rev_F at 25); Ex. 1 (CG000407_VisiumSpatialGeneExpressionforFFPE_UserGuide_RevD) at 29. To the extent Visium and related products are argued by Counterclaim-Defendant or found by the Court not to literally infringe certain limitations of the '689 Patent, infringement of such limitations can be found under the doctrine of equivalents.
15. The method of claim 1, wherein steps (d) and (e) are performed simultaneously.	10x's Visium performs steps (d) and (e) of claim 1 simultaneously. For example: <i>See supra</i> analysis for Claim 1. Each step of the Visium workflow takes place across the whole tissue sample which covers the approximately 5,000 gene expression spots (<i>e.g.</i>, locations). "Always cover the tissue section completely when adding reagents to the well. A gentle tap may help spread the reagent more evenly." 10XN653-00060087 at 60111 (CG000239_Visium_Spatial_Gene_Expression_User_Guide_Rev_F at 25); Ex. 1 (CG000407_VisiumSpatialGeneExpressionforFFPE_UserGuide_RevD) at 29.

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
	To the extent Visium and related products are argued by Counterclaim-Defendant or found by the Court not to literally infringe certain limitations of the '689 Patent, infringement of such limitations can be found under the doctrine of equivalents.
16. A method for spatially detecting at least one target analyte in a first location and a second location of a tissue sample comprising:	To the extent that the preamble is found to be limiting, 10X's Visium for FFPE are designed and marketed such that they will be used, and are in fact used, to spatially detect at least one target analyte in a first location and a second location of a tissue. For example: <i>See supra</i> analysis for Claim 1(a). To the extent Visium and related products are argued by Counterclaim-Defendant or found by the Court not to literally infringe certain limitations of the '689 Patent, infringement of such limitations can be found under the doctrine of equivalents.
a) contacting the tissue sample with a first plurality of nucleic acid probes and a second plurality of nucleic acid probes, wherein each of the nucleic acid probes in the first plurality of nucleic acid probes comprise a target binding domain that binds to the at least one target analyte, wherein each of the nucleic acid probes in the second plurality of nucleic	10x's Visium for FFPE performs a method comprising contacting the contacting the tissue sample with a first plurality of nucleic acid probes and a second plurality of nucleic acid probes. For example: <i>See supra</i> analysis for Claim 1(a) and the preamble of Claim 1. To the extent Visium and related products are argued by Counterclaim-Defendant or found by the Court not to literally infringe certain limitations of the '689 Patent, infringement of such limitations can be found under the doctrine of equivalents.

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
acid probes comprise a target binding domain that binds to the at least one target analyte, wherein the tissue sample is treated to facilitate binding of the first plurality of nucleic acid probes and the second plurality of nucleic acid probes to the at least one target analyte;	
b) forming ligated probes by ligating each of nucleic acid probes from the first plurality of nucleic acid probes and each of nucleic acid probes from the second plurality of nucleic acid probes that are bound to each of identical molecules from the at least one target analyte;	10x's Visium for FFPE performs a method comprising forming ligated probes by ligating each of nucleic acid probes from the first plurality of nucleic acid probes and each of nucleic acid probes from the second plurality of nucleic acid probes that are bound to each of identical molecules from the at least one target analyte. For example: <i>See supra</i> analysis for Claim 16(a). “Human or mouse whole transcriptome probe panels, consisting of a pair of specific probes for each targeted gene, are then added to the tissue. These probe pairs hybridize to their gene target and are then ligated to one another.” Ex. 1 (CG000407_VisiumSpatialGeneExpressionforFFPE_UserGuide_RevD) at 18. Step 1 Probe Hybridization. The human or mouse whole transcriptome probe panel, consisting of a pair of specific probes for each targeted gene, is added to the deparaffinized, stained, and decrosslinked tissues. Together, probe pairs hybridize to their complementary target RNA. Step 2 Probe Ligation. After hybridization, a ligase is added to seal the junction between the probe pairs that have hybridized to RNA, forming a ligation product. <i>Id.</i> at 19.

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
	<i>Id.</i> To the extent Visium and related products are argued by Counterclaim-Defendant or found by the Court not to literally infringe certain limitations of the '689 Patent, infringement of such limitations can be found under the doctrine of equivalents.
c) collecting the ligated probes, or portions thereof, bound to the at least one target analyte in a first location of the tissue sample under conditions that release the ligated probes, or portions thereof, from the first location of the tissue sample;	10X's Visium for FFPE performs a method comprising collecting the ligated probes, or portions thereof, bound to the at least one target analyte in a first location of the tissue sample under conditions that release the ligated probes, or portions thereof, from the first location of the tissue sample. For example: <i>See supra</i> analysis for Claim 1(b). To the extent Visium and related products are argued by Counterclaim-Defendant or found by the Court not to literally infringe certain limitations of the '689 Patent, infringement of such limitations can be found under the doctrine of equivalents.
d) collecting the ligated probes, or portions thereof, bound to each of identical molecules from the at least one target analyte in a second	10X's Visium for FFPE performs a method comprising collecting the ligated probes, or portions thereof, bound to each of identical molecules from the at least one target analyte in a second location of the tissue sample under conditions that release the probes, or portions thereof, from the second location of the tissue sample. For example: <i>See supra</i> analysis for Claims 1(b) and 1(c).

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
location of the tissue sample under conditions that release the probes, or portions thereof, from the second location of the tissue sample;	To the extent Visium and related products are argued by Counterclaim-Defendant or found by the Court not to literally infringe certain limitations of the '689 Patent, infringement of such limitations can be found under the doctrine of equivalents.
e) performing an extension reaction that incorporates at least one nucleic acid sequence that identifies the first location of the tissue sample into each of the ligated probes, or portions thereof, collected in step (c), thereby forming a first plurality of extension products that comprise the ligated probes, or portions thereof, collected in step (c) and the at least one nucleic acid sequence that identifies the first location of the tissue sample;	10X's Visium for FFPE performs a method comprising performing an extension reaction that incorporates at least one nucleic acid sequence (primer sequence containing spatial barcode) that identifies the first location of the tissue sample into each of the ligated probes, or portions thereof, collected in step (c), thereby forming a first plurality of extension products (spatially barcoded, ligated probe products) that comprise the ligated probes, or portions thereof, collected in step (c) and the at least one nucleic acid sequence that identifies the first location of the tissue sample. For example: <i>See supra</i> analysis for Claim 1(d). To the extent Visium and related products are argued by Counterclaim-Defendant or found by the Court not to literally infringe certain limitations of the '689 Patent, infringement of such limitations can be found under the doctrine of equivalents.
f) performing an extension reaction that incorporates at least one nucleic acid sequence that identifies the second location of the tissue sample into each of the ligated probes, or	10X's Visium for FFPE performs a method comprising performing an extension reaction that incorporates at least one nucleic acid sequence that identifies the second location of the tissue sample into each of the ligated probes, or portions thereof, collected in step (d), thereby forming a second plurality extension products that comprise the ligated probes, or portions thereof, collected in step (d) and the at least one nucleic acid sequence that identifies the at least second location of the tissue sample. For example:

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
portions thereof, collected in step (d), thereby forming a second plurality extension products that comprise the ligated probes, or portions thereof, collected in step (d) and the at least one nucleic acid sequence that identifies the at least second location of the tissue sample; and	<i>See supra</i> analysis for Claims 1(d) and 1(e). To the extent Visium and related products are argued by Counterclaim-Defendant or found by the Court not to literally infringe certain limitations of the '689 Patent, infringement of such limitations can be found under the doctrine of equivalents.
g) identifying the first plurality of extension products and the second plurality of extension products by sequencing the first plurality of extension products and the second plurality of extension products, thereby spatially detecting the at least one target analyte in the first location and the second location of the tissue sample.	10X's Visium for FFPE performs a method comprising identifying the first plurality of extension products and the second plurality of extension products by sequencing the first plurality of extension products and the second plurality of extension products, thereby spatially detecting the at least one target analyte in the first location and the second location of the tissue sample. For example: <i>See supra</i> analysis for Claim 1(f). To the extent Visium and related products are argued by Counterclaim-Defendant or found by the Court not to literally infringe certain limitations of the '689 Patent, infringement of such limitations can be found under the doctrine of equivalents.
17. The method of claim 16, wherein the tissue sample is a formalin-fixed paraffin-embedded (FFPE) tissue sample.	10X's Visium for FFPE performs the method wherein the tissue sample is a formalin-fixed paraffin-embedded (FFPE) tissue sample. For example: <i>See supra</i> for Claims 2 and 16.

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
	To the extent Visium and related products are argued by Counterclaim-Defendant or found by the Court not to literally infringe certain limitations of the '689 Patent, infringement of such limitations can be found under the doctrine of equivalents.
18. The method of claim 16, wherein the tissue sample is immobilized onto a microscope slide.	10X's Visium for FFPE performs the method wherein the tissue sample immobilized onto a microscope slide. For example: <i>See supra</i> analysis for Claim 3 and 16. To the extent Visium and related products are argued by Counterclaim-Defendant or found by the Court not to literally infringe certain limitations of the '689 Patent, infringement of such limitations can be found under the doctrine of equivalents.
19. The method of claim 18, wherein the microscope slide comprises a plurality of primers immobilized on the microscope slide.	10X's Visium for FFPE performs the method wherein microscope slide comprises a plurality of primers immobilized on the microscope slide. For example: <i>See supra</i> analysis for Claim 4 and 18. To the extent Visium and related products are argued by Counterclaim-Defendant or found by the Court not to literally infringe certain limitations of the '689 Patent, infringement of such limitations can be found under the doctrine of equivalents.
20. The method of claim 19, wherein the plurality of primers is immobilized on the microscope slide at their 5' ends.	10x's Visium for FFPE performs the method wherein the plurality of primers is immobilized on the microscope slide at their 5' ends. For example: <i>See supra</i> infringement analysis for Claims 5 and 19.

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
	To the extent Visium and related products are argued by Counterclaim-Defendant or found by the Court not to literally infringe certain limitations of the '689 Patent, infringement of such limitations can be found under the doctrine of equivalents.
21. The method of claim 20, wherein each of step (e) and step (f) comprise performing a solid-phase amplification reaction, wherein the solid-phase amplification reaction is carried out on the microscope slide using the plurality of primers immobilized on the microscope slide.	10x's Visium for FFPE performs the method wherein each of step (e) and step (f) of claim 20 comprise performing a solid-phase amplification reaction, wherein the solid-phase amplification reaction is carried out on the microscope slide using the plurality of primers immobilized on the microscope slide. For example: <i>See supra</i> analysis for Claims 6 and 20. To the extent Visium and related products are argued by Counterclaim-Defendant or found by the Court not to literally infringe certain limitations of the '689 Patent, infringement of such limitations can be found under the doctrine of equivalents.
23. The method of claim 16, further comprising amplifying a library using the first plurality of extension products and the second plurality of extension products as templates.	10x's Visium for FFPE performs the method wherein amplifying a library using the first plurality of extension products and the second plurality of extension products as templates. For example: <i>See supra</i> analysis for Claims 8 and 16. To the extent Visium and related products are argued by Counterclaim-Defendant or found by the Court not to literally infringe certain limitations of the '689 Patent, infringement of such limitations can be found under the doctrine of equivalents.
24. The method of claim 16, wherein the at least one nucleic acid sequence that identifies the first location of the tissue sample comprises at least one	10x's Visium for FFPE performs the method wherein the at least one nucleic acid sequence that identifies the first location of the tissue sample comprises at least one unique molecular identifier. For example: <i>See supra</i> analysis for Claims 9 and 16.

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
unique molecular identifier.	To the extent Visium and related products are argued by Counterclaim-Defendant or found by the Court not to literally infringe certain limitations of the '689 Patent, infringement of such limitations can be found under the doctrine of equivalents.
25. The method of claim 16, wherein the at least one nucleic acid sequence that identifies the second location of the tissue sample comprises at least one unique molecular identifier.	10x's Visium for FFPE performs the method wherein the at least one nucleic acid sequence that identifies the second location of the tissue sample comprises at least one unique molecular identifier. For example: <i>See supra</i> analysis for Claims 10 and 16. To the extent Visium and related products are argued by Counterclaim-Defendant or found by the Court not to literally infringe certain limitations of the '689 Patent, infringement of such limitations can be found under the doctrine of equivalents.
26. The method of claim 16, wherein the nucleic acid probes in the first plurality of nucleic acid probes comprise an amplification primer binding site, the nucleic acid probes in the second plurality of nucleic acid probes comprise an amplification primer binding site, or both nucleic acid probes in the first plurality of nucleic acid probes comprise an amplification primer binding site and the nucleic acid probes in the	10x's Visium for FFPE performs the method wherein the nucleic acid probes in the first plurality of nucleic acid probes comprise an amplification primer binding site, the nucleic acid probes in the second plurality of nucleic acid probes comprise an amplification primer binding site, or both nucleic acid probes in the first plurality of nucleic acid probes comprise an amplification primer binding site and the nucleic acid probes in the second plurality of nucleic acid probes comprise an amplification primer binding site. For example: <i>See supra</i> analysis for Claim 16. In Visium workflow for FFPE, the DNA products comprise at least the TruSeq Read 1 and Read 2s amplification primer binding sites. At least the Read 2s amplification primer binding site is included in the first/second plurality of nucleic acid probes (<i>e.g.</i>, the "LHS" probe). "Step 1 Probe Hybridization. The human or mouse whole transcriptome probe panel, consisting of a pair of specific probes for each targeted gene, is added to the deparaffinized, stained, and decrosslinked tissues. Together, probe pairs hybridize to their complementary target RNA." <i>Id.</i> at 19.

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
second plurality of nucleic acid probes comprise an amplification primer binding site.	<i>Id.</i> Step 4 Visium Spatial Gene Expression - FFPE Library Construction. The spatially barcoded, ligated probe products are released from the slide and harvested for qPCR to determine Sample Index PCR cycle number. The products then undergo indexing via Sample Index PCR. This, in turn, generates final library molecules that are cleaned up by SPRIselect, assessed on a bioanalyzer or a similar instrument, quantified, and then sequenced. <i>Id.</i> at 21.


OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
	The diagram illustrates the 10X Visium sequencing process. It shows a DNA construct with various regions: P5 (blue), i5 (grey), Read 1 (black), a Ligated Probe Insert (orange), Read 2S (black), i7 (grey), and P7 (yellow). An arrow labeled 'Sample Index PCR' points to the bottom part of the diagram, which shows the same construct after PCR, with the addition of a Spatial Barcode (green) and UMI (red) between Read 1 and the Ligated Probe Insert. <i>Id.</i> FFPE libraries comprise standard Illumina paired-end constructs which begin with P5 and end with P7. 16 bp Spatial Barcodes are encoded at the start of TruSeq Read 1, while i7 and i5 sample index sequences are incorporated as the index read. TruSeq Read 1 and Small RNA Read 2 (Read 2s) are standard Illumina sequencing primer sites used in paired-end sequencing. TruSeq Read 1 is used to sequence 16 bp Spatial Barcode and 12 bp UMI. Small RNA Read 2 (Read 2S) is used to sequence the Ligated Probe Insert. Sequencing these libraries produces a standard Illumina BCL data output folder. <i>Id.</i> at 60. To the extent Visium and related products are argued by Counterclaim-Defendant or found by the Court not to literally infringe certain limitations of the '689 Patent, infringement of such limitations can be found under the doctrine of equivalents.
27. The method of claim 16, wherein the at least one nucleic acid sequence that identifies the first location of the tissue sample	10x's Visium for FFPE performs the method wherein the at least one nucleic acid sequence that identifies the first location of the tissue sample comprises at least one amplification primer binding site, the at least one nucleic acid sequence that identifies the second location of the tissue sample comprises at least one amplification primer binding site, or both the at least one nucleic acid sequence that identifies the first

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
comprises at least one amplification primer binding site, the at least one nucleic acid sequence that identifies the second location of the tissue sample comprises at least one amplification primer binding site, or both the at least one nucleic acid sequence that identifies the first location of the tissue sample and the at least one nucleic acid sequence that identifies the second location of the tissue sample comprise at least one amplification primer binding site.	location of the tissue sample and the at least one nucleic acid sequence that identifies the second location of the tissue sample comprise at least one amplification primer binding site. For example: <i>See supra</i> analysis for Claims 11, 12, and 16. To the extent Visium and related products are argued by Counterclaim-Defendant or found by the Court not to literally infringe certain limitations of the '689 Patent, infringement of such limitations can be found under the doctrine of equivalents.
28. The method of claim 16, wherein the target binding domain of each probe from the first plurality of nucleic acid probes and the second plurality of nucleic acid probes comprises a single-stranded nucleic acid molecule.	10x's Visium for FFPE performs the method wherein the target binding domain of each probe from the first plurality of nucleic acid probes and the second plurality of nucleic acid probes comprises a single-stranded nucleic acid molecule. For example: <i>See supra</i> analysis for Claim 16. In Visium for FFPE workflow, the pair of specific probes for each targeted gene are single stranded nucleic acid molecules. Step 1 Probe Hybridization. The human or mouse whole transcriptome probe panel, consisting of a pair of specific probes for each targeted gene, is added to the

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
	deparaffinized, stained, and decrosslinked tissues. Together, probe pairs hybridize to their complementary target RNA. Step 2 Probe Ligation. After hybridization, a ligase is added to seal the junction between the probe pairs that have hybridized to RNA, forming a ligation product. Step 3 Probe Release & Extension The single stranded ligation products are released from the tissue upon RNase treatment and permeabilization, and then captured on the Visium slides. <i>Id.</i> at 19-20.  The diagram illustrates the 10X Visium workflow in four stages: Initial State: A tissue section is shown above a Visium slide. Below, a target mRNA molecule is shown with a 5' end labeled '5' Read 2S' and a 3' end labeled '3' AAAAAAAAAA'. The mRNA is flanked by 3' and 5' ends. RNA Digestion: An arrow labeled 'RNA Digestion' points to the next stage. Probe Release: An arrow labeled 'Probe Release' points to the next stage. Capture on Surface: An arrow labeled 'Capture on Surface' points to the final stage. The final stage shows a 'Slide' with a 'Read 1' (black bar) and a 'Spatial Barcode' (green bar). The 'Read 1' is labeled '3' AAAAAAAAAA' and the 'Spatial Barcode' is labeled '5' Read 2S'. The 'Read 1' is also labeled 'Poly(dT)VN' and the 'Spatial Barcode' is labeled 'UMI'. <i>Id.</i>

OUTSIDE ATTORNEYS' EYES ONLY INFORMATION

the '689 Patent	10X's Visium ¹
	To the extent Visium and related products are argued by Counterclaim-Defendant or found by the Court not to literally infringe certain limitations of the '689 Patent, infringement of such limitations can be found under the doctrine of equivalents.
29. The method of claim 16, wherein steps (c) and (d) are performed simultaneously.	10x's Visium for FFPE performs the steps (c) and (d) of claim 16 simultaneously. For example: <i>See supra</i> analysis for Claims 14 and 16. To the extent Visium and related products are argued by Counterclaim-Defendant or found by the Court not to literally infringe certain limitations of the '689 Patent, infringement of such limitations can be found under the doctrine of equivalents.
30. The method of claim 16, wherein steps (e) and (f) are performed simultaneously.	10x's Visium for FFPE performs the steps (e) and (f) of claim 16 simultaneously. For example: <i>See supra</i> analysis for Claims 15 and 16. To the extent Visium and related products are argued by Counterclaim-Defendant or found by the Court not to literally infringe certain limitations of the '689 Patent, infringement of such limitations can be found under the doctrine of equivalents.

EXHIBIT 1

User Guide | CG000407 | Rev D

Visium Spatial Gene Expression Reagent Kits for FFPE

For use with:

Visium Spatial Gene Expression Slide Kit, 16 rxns *PN-1000185* | 4 rxns *PN-1000188*

Visium Tissue Section Test Slides, 4 Pack, *PN-1000347*

Visium FFPE Reagent Kit, Large *PN-1000362* | Small *PN-1000361*

Visium Human Transcriptome Probe Kit, Large *PN-1000364* | Small *PN-1000363*

Visium Mouse Transcriptome Probe Kit, Large *PN-1000366* | Small *PN-1000365*

Visium Accessory Kit, *PN-1000194*

Dual Index Kit TS Set A, 96 rxns *PN-1000251*

Notices

Document Number

CG000407 | Rev D

Legal Notices

© 2022 10x Genomics, Inc (10x Genomics). All rights reserved. Duplication and/or reproduction of all or any portion of this document without the express written consent of 10x Genomics, is strictly forbidden. Nothing contained herein shall constitute any warranty, express or implied, as to the performance of any products described herein. Any and all warranties applicable to any products are set forth in the applicable terms and conditions of sale accompanying the purchase of such product. 10x Genomics provides no warranty and hereby disclaims any and all warranties as to the use of any third-party products or protocols described herein. The use of products described herein is subject to certain restrictions as set forth in the applicable terms and conditions of sale accompanying the purchase of such product. A non-exhaustive list of 10x Genomics' marks, many of which are registered in the United States and other countries can be viewed at: www.10xgenomics.com/trademarks. 10x Genomics may refer to the products or services offered by other companies by their brand name or company name solely for clarity, and does not claim any rights in those third party marks or names. 10x Genomics products may be covered by one or more of the patents as indicated at: www.10xgenomics.com/patents. The use of products described herein is subject to 10x Genomics Terms and Conditions of Sale, available at www.10xgenomics.com/legal-notices, or such other terms that have been agreed to in writing between 10x Genomics and user. All products and services described herein are intended FOR RESEARCH USE ONLY and NOT FOR USE IN DIAGNOSTIC PROCEDURES.

Licensed Software Updates Warranties

Updates to existing Licensed Software may be required to enable customers to use new or existing products.

Support

Email: support@10xgenomics.com

10x Genomics

6230 Stoneridge Mall Road

Pleasanton, CA 94588 USA

Document Revision Summary

Document Number

CG000407 | Rev D

Title

Visium Spatial Gene Expression Reagent Kits for FFPE - User Guide

Revision

Rev D

Revision Date

May 2022

Specific Changes

- Updated and highlighted orderable kits in blue (page 7)
- Updated to include KAPA SYBR provider (page 15)
- Updated 10X PBS as a required reagent in the getting started table in Probe Hybridization step (page 39)
- Updated SI-PCR Cq value recommendation (page 56)

General Changes

Updated for general minor consistency of language and terms throughout

Table of Contents

Introduction	6
Reagent Kits	7
10x Genomics Accessories	12
Recommended Thermal Cyclers	12
Recommended Real Time qPCR Systems	12
Recommended Imaging Systems	13
Additional Kits, Reagents & Equipment	15
Protocol Steps & Timing	17
Stepwise Objectives	18
Tips & Best Practices	22
Sample Preparation, Deparaffinization & Staining Guidelines	34
Workflow Overview	35
Sample Preparation Guidelines	36
Deparaffinization, Staining & Decrosslinking Guidelines	37
Step 1	38
Probe Hybridization	39
1.1 Probe Hybridization	40
Step 2	42
Probe Ligation	43
2.1 Post Hybridization Wash	44
2.2 Probe Ligation	45
2.3 Post Ligation Wash	46
Step 3	47
Probe Release & Extension	48
3.1 RNA Digestion & Probe Release	49
3.2 Probe Extension	51
3.3 Probe Elution	52
Step 4	53
Visium Spatial Gene Expression –FFPE Library Construction	54
4.1 Cycle Number Determination – qPCR	55
4.2 Sample Index PCR	56
4.3 Post Sample Index PCR Cleanup – SPRIselect	57
4.4 Post Library Construction QC	58

Sequencing	59
Troubleshooting	62
Appendix	66
Post Library Construction Quantification	67
Agilent TapeStation Traces	68
LabChip Traces	68
Assay Scheme	69
Sequences	71

Introduction

Visium Spatial Gene Expression for FFPE Reagent Kits

Visium Accessories

Recommended Thermal Cyclers

Recommended Real Time qPCR Systems

Recommended Imaging Systems

Additional Kits, Reagents & Equipment

Protocol Steps & Timing

Stepwise Objectives

Reagent Kits

Visium Spatial Gene Expression for FFPE Reagent Kits

Refer to SDS for handling and disposal information

Orderable Reagents Kits	Part Number	Components (Part Number)
Visium Spatial for FFPE Gene Expression Kit, Human Transcriptome	1000334	Visium Spatial Gene Expression Slide Kit, 16 rxns (PN-1000185)
		Visium FFPE Reagent Kit – Large (PN-1000362)
		Visium Human Transcriptome Probe Kit – Large (PN-1000364)
		Visium Accessory Kit (PN-1000194)
		Dual Index Plate TS Set A (PN-1000251)
Visium Spatial for FFPE Gene Expression Starter Kit, Mouse Transcriptome	1000335	Visium Spatial Gene Expression Slide Kit, 16 rxns (PN-1000185)
		Visium FFPE Reagent Kit – Large (PN-1000362)
		Visium Mouse Transcriptome Probe Kit – Large (PN-1000366)
		Visium Accessory Kit (PN-1000194)
		Dual Index Plate TS Set A (PN-1000251)
Visium Spatial for FFPE Gene Expression Kit, Human Transcriptome, 16 rxns	1000336	Visium Spatial Gene Expression Slide Kit, 16 rxns (PN-1000185)
		Visium FFPE Reagent Kit – Large (PN-1000362)
		Visium Human Transcriptome Probe Kit – Large (PN-1000364)
Visium Spatial for FFPE Gene Expression Kit, Mouse Transcriptome, 16 rxns	1000337	Visium Spatial Gene Expression Slide Kit, 16 rxns (PN-1000185)
		Visium FFPE Reagent Kit, Large (PN-1000362)
		Visium Mouse Transcriptome Probe Kit – Large (PN-1000366)
Visium Spatial for FFPE Gene Expression Kit, Human Transcriptome, 4 rxns	1000338	Visium Spatial Gene Expression Slide Kit, 4 rxns (PN-1000188)
		FFPE Reagent Kit – Small (PN-1000361)
		Visium Human Transcriptome Probe Kit – Small (PN-1000363)
Visium Spatial for FFPE Gene Expression Kit, Mouse Transcriptome, 4 rxns	1000339	Visium Spatial Gene Expression Slide Kit, 4 rxns (PN-1000188)
		Visium FFPE Reagent Kit – Small (PN-1000361)
		Visium Mouse Transcriptome Probe Kit – Small (PN-1000365)

Refer to page 7 for orderable parts.

Visium Spatial Gene Expression Slide Kit, 16 rxns PN-1000185

Visium

Spatial Gene Expression Slide Kit

16 rxns, PN-1000185

store at ambient temperature

	#	PN
Visium Spatial Gene Expression Slide	4	2000233
*Visium Slide Seals, 40-pack	1	2000284
Visium Cassette & Gasket Assembly, 4-pack	1	2000282

10x
GENOMICS

Visium Spatial Gene Expression Slide Kit, 4 rxns PN-1000188

Visium

Spatial Gene Expression Slide Kit

4 rxns, PN-1000188

store at ambient temperature

	#	PN
Visium Spatial Gene Expression Slide	1	2000233
*Visium Slide Seals, 12-pack	1	2000283
Visium Cassette & Gasket Assembly, 1-pack	1	2000281

10x
GENOMICS

*Visium Slide Seals may come in varying dimensions and quantities in different lots. Check the number of slide seals in the kit. Additional seals may be required. Refer to page 30 ([Visium Slide Seal Application & Removal](#)) of this User Guide for instructions on how to resize seals or cut additional seals.

Visium Tissue Section Test Slides, 4 Pack PN-1000347

Visium

Tissue Section Test Slides

4 Pack, PN-1000347

store at ambient temperature

	#	PN
Visium Tissue Section Test Slide	4	2000460

10x
GENOMICS

Visium FFPE Reagent Kit – Large PN-1000362

Visium FFPE Reagent Kit – Large

PN-1000362

Store at -20°C

	#	PN
○ Amp Mix	1	2000047
● Extension Enzyme	1	2000427
● Extension Buffer	1	2000409
● RNase Enzyme	1	3000605
● 2X RNase Buffer	1	2000411
● Perm Enzyme B	1	3000602
● Perm Buffer B	1	2000413
● TS Primer Mix A	1	2000447

10x
genomics

Visium FFPE Reagent Kit – Small PN-1000361

Visium FFPE Reagent Kit – Small

PN-1000361

Store at -20°C

	#	PN
○ Amp Mix	1	2000131
● Extension Enzyme	1	2000389
● Extension Buffer	1	2000408
● RNase Enzyme	1	3000593
● 2X RNase Buffer	1	2000410
● Perm Enzyme B	1	3000553
● Perm Buffer B	1	2000412
● TS Primer Mix A	1	2000447

10x
genomics

Visium Human Transcriptome Probe Kit – Large PN-1000364

Visium

Human Transcriptome Probe Kit – Large

PN-1000364

Store at -20°C

	#	PN
FFPE Hyb Buffer	1	2000423
FFPE Post-Hyb Wash Buffer	3	2000424
● Human WT Probes – RHS	1	2000453
● Human WT Probes – LHS	1	2000454
○ Probe Ligation Enzyme	1	2000426
○ 2X Probe Ligation Buffer	1	2000446
Post Ligation Wash Buffer	1	2000420

10x
GENOMICS

Visium Human Transcriptome Probe Kit – Small PN-1000363

Visium

Human Transcriptome Probe Kit – Small

PN-1000363

Store at -20°C

	#	PN
FFPE Hyb Buffer	1	2000423
FFPE Post-Hyb Wash Buffer	1	2000424
● Human WT Probes – RHS	1	2000449
● Human WT Probes – LHS	1	2000450
○ Probe Ligation Enzyme	1	2000425
○ 2X Probe Ligation Buffer	1	2000445
Post Ligation Wash Buffer	1	2000419

10x
GENOMICS

Visium Mouse Transcriptome Probe Kit – Large PN-1000366

Visium

Mouse Transcriptome Probe Kit – Large

PN-1000366

Store at -20°C

	#	PN
FFPE Hyb Buffer	1	2000423
FFPE Post-Hyb Wash Buffer	3	2000424
● Mouse WT Probes – RHS	1	2000457
● Mouse WT Probes – LHS	1	2000458
○ Probe Ligation Enzyme	1	2000426
○ 2X Probe Ligation Buffer	1	2000446
Post Ligation Wash Buffer	1	2000420

10x
genomics

Visium Mouse Transcriptome Probe Kit – Small PN-1000365

Visium

Mouse Transcriptome Probe Kit – Small

PN-1000365

Store at -20°C

	#	PN
FFPE Hyb Buffer	1	2000423
FFPE Post-Hyb Wash Buffer	1	2000424
● Mouse WT Probes – RHS	1	2000455
● Mouse WT Probes – LHS	1	2000456
○ Probe Ligation Enzyme	1	2000425
○ 2X Probe Ligation Buffer	1	2000445
Post Ligation Wash Buffer	1	2000419

10x
genomics

Dual Index Kit TS Set A, 96 rxns PN-1000251

Dual Index Kit TS Set A

Store at -20°C

	#	PN
Dual Index Plate TS Set A	1	3000511

10x Genomics Accessories

Product	Part Number (Kit)	Part Number (Item)
Thermocycler Adaptor		3000380
Visium Spatial Imaging Test Slide	1000194	2000235
10x Magnetic Separator		230003
Slide Alignment Tool		3000433

Recommended Thermal Cyclers

Supplier	Description	Part Number
Bio-Rad	C1000 Touch Thermal Cycler with 96-Deep Well Reaction Module	1851197
Eppendorf	MasterCycler Pro (discontinued)	North America 950030010 International 6321 000.019
Thermo Fisher Scientific	Veriti 96-Well Thermal Cycler	4375786

Recommended Real Time qPCR Systems

Supplier	Description	Part Number
Applied Biosystems	QuantStudio 12K Flex system	4471087
Bio-Rad	CFX96 Real-time System	1855096

Recommended Imaging Systems

The imaging systems listed below were used by 10x Genomics. Any equivalent system with the listed features may be used for imaging. Hardware compatibility may be tested by using the Visium Spatial Imaging Test Slide (included in Visium Accessory Kit). Consult the Visium Spatial Gene Expression for FFPE Imaging Guidelines Technical Note (CG000436) for more information.

Imaging Systems & Specifications		
Microscopes (Any equivalent system with the listed features may be used for imaging)		
Supplier	Model	Configuration
Thermo Fisher Scientific	EVOS M7000	Inverted
Leica	Aperio Versa 8	Upright
	Leica DMI8	Inverted
MetaSystems	Metafer	Upright
Nikon	Nikon Eclipse Ti2	Inverted
BioTek	Cytation 7	Inverted or Upright
Keyence	Keyence BZX800	Inverted
Microscope Features		
Objectives	10X, NA 0.45 20X, NA 0.75 40X, NA 0.95	
Automated Scanning Stage	Microscope tile scanning functionality is required for imaging tissue sections placed on a Capture Area of a Visium Spatial slide.	
Brightfield Features (for H&E staining)	Color camera (3 x 8 bit, 2,424 x 2,424 pixel resolution) White balancing functionality Minimum Capture Resolution 2.18 µm/pixel Exposure times 2-10 milli sec	
Fluorescence Features (for IF staining)	Light source (or equivalent) with a wavelength range of 380-680 nm Monochrome camera (14 bit, 2,424 x 2,424 pixel resolution) DAPI filter cube (Excitation 392/23, Emission 447/60) FITC filter cube (Excitation 480/40, Emission 535/50) TRITC filter cube (Excitation 542/20, Emission 620/52) Cy5 filter cube (Excitation 618/50, Emission 698/70) Minimum Capture Resolution 2.18 µm/pixel Exposure times 100 milli sec-2 sec	
Additional Specifications		
Image Format	Save image as a tiff (preferred) or jpeg	
Computer	Computer with sufficient power to handle large images (0.5-5 GB)	
Software	Image stitching software (microscope's software or equivalent, like Image J)	

Image Capture Guidelines:

The 8 x 8 mm area that includes the fiducial frame and the Capture Area with the tissue section should be represented by $\geq 2,000 \times 2,000$ pixel portion of the image.

When setting the microscope for imaging individual Capture Area, the imaging area should be ~1-2 mm beyond the fiducial frame for optimal imaging alignment. Minimize imaging of any adjacent Capture Area/s when taking images of a specific Capture Area with a tissue section. For lossy compression, such as jpeg, the quality level should be kept high enough to represent the fiducial frame crisply and without artifacts.

Additional Kits, Reagents & Equipment

The items in the table below have been validated by 10x Genomics and are highly recommended for the Visium Spatial Gene Expression for FFPE. Substituting materials may adversely affect system performance. This list does not include standard laboratory equipment such as water baths, centrifuges, vortex mixers, pH meters, freezers etc.

Item	Description	Supplier	Part Number
Plastics			
1.5 ml tubes	DNA LoBind Tubes, 1.5 ml	Eppendorf	022431021
2.0 ml tubes	DNA LoBind Tubes, 2.0 ml <i>when processing more than two slides</i>	Eppendorf	022431048
0.2 ml PCR 8-tube strips	PCR Tubes 0.2 ml 8-tube strips	Eppendorf	951010022
	TempAssure PCR 8-tube strip	USA Scientific	1402-4700
	MicroAmp 8-Tube Strip, 0.2 ml	Thermo Fisher Scientific	N8010580
	MicroAmp 8-Cap Strip, clear	Thermo Fisher Scientific	N8010535
Slide mailer/tube	Simport Scientific LockMailer Tamper Evidence Slide Mailer	Thermo Fisher Scientific	22-038-399
	Self-Standing Polypropylene Centrifuge Tubes (50 ml), sterile <i>Alternative to slide mailer</i>	Corning	430921
PCR plates and sealing film	Hard-shell PCR Plates 96-well, thin wall (pkg of 50) <i>Or any compatible PCR Plate</i>	Bio-Rad	HSP9665
	Microseal 'B' PCR Plate Sealing Film, adhesive	Bio-Rad	MSB1001
Pipette tips	Tips LTS 200UL Filter RT-L200FLR	Rainin	30389240
	Tips LTS 1ML Filter RT-L1000FLR	Rainin	30389213
	Tips LTS 20UL Filter RT-L10FLR	Rainin	30389226
Reagent reservoirs	Divided Polystyrene Reservoirs	VWR	41428-958
Kits & Reagents			
Nuclease-free water	Nuclease-free Water (not DEPC-Treated)	Thermo Fisher Scientific	AM9937
Tris 1 M (<i>Tris-HCl</i>)	Tris 1 M, pH 7.0, RNase-free	Thermo Fisher Scientific	AM9850G
Plain glass slides	Fisherbrand Premier Plain Glass Microscope Slides, <i>Optional</i>	Thermo Fisher Scientific	12-544-4
10X PBS	PBS - Phosphate Buffered Saline (10X) pH 7.4, RNase-free	Thermo Fisher Scientific	AM9624
Tween 20	Tween 20 Surfact-Amps Detergent Solution (10% solution)	Thermo Fisher Scientific	28320
Roche (US, some Canadian Provinces) Millipore Sigma (Europe, Asia, & some Canadian Provinces)	KAPA SYBR FAST qPCR Master Mix (2X)		KK4600
SPRIsselect reagent	SPRIsselect Reagent Kit	Beckman Coulter	B23318

Additional Kits, Reagents & Equipment

The items in the table below have been validated by 10x Genomics and are highly recommended for the Visium Spatial Gene Expression for FFPE. Substituting materials may adversely affect system performance. This list does not include standard laboratory equipment such as water baths, centrifuges, vortex mixers, pH meters, freezers etc.

Item	Description	Supplier	Part Number	
Kits & Reagents				
Ethanol	Ethyl Alcohol, Pure (200 Proof, anhydrous)	Millipore Sigma	E7023-500ML	
8 M KOH	Potassium Hydroxide Solution, 8M	Millipore Sigma	P4494-50ML	
20X SSC buffer	SSC Buffer 20X Concentrate	Millipore Sigma	S6639-1L	
Buffer EB	Qiagen Buffer EB	Qiagen	19086	
Ultrapure water	Ultrapure/Milli-Q water, <i>from Milli-Q Integral Ultrapure Water System or equivalent</i>	–	-	
Equipment				
Pipettes	Pipet-Lite Multi Pipette L8-200XLS+	Rainin	17013805	
	Pipet-Lite LTS Pipette L-2XLS+	Rainin	17014393	
	Pipet-Lite LTS Pipette L-10XLS+	Rainin	17014388	
	Pipet-Lite LTS Pipette L-20XLS+	Rainin	17014392	
	Pipet-Lite LTS Pipette L-100XLS+	Rainin	17014384	
	Pipet-Lite LTS Pipette L-200XLS+	Rainin	17014391	
	Pipet-Lite LTS Pipette L-1000XLS+	Rainin	17014382	
Mini centrifuge	VWR Mini Centrifuge <i>Or any equivalent mini centrifuge</i>	VWR	76269-064	
Quantification & Quality Control				
Bioanalyzer & associated reagents	2100 Bioanalyzer Laptop Bundle (discontinued) (Replacement 2100 Bioanalyzer Instrument/ 2100 Expert Laptop Bundle)		Agilent	G2943CA G2939BA/ G2953CA
	High Sensitivity DNA Kit		Agilent	5067-4626
TapeStation & associated reagents	4200 TapeStation	Choose Bioanalyzer, TapeStation or LabChip based on availability & preference.	Agilent	G2991AA
	High Sensitivity D1000: ScreenTape/ Reagents		Agilent	5067-5592/ 5067-5593
	High Sensitivity D5000: ScreenTape/ Reagents		Agilent	5067-5584/ 5067-5585
LabChip & associated reagents	LabChip GX Touch HT Nucleic Acid Analyzer		PerkinElmer	CLS137031
	DNA High Sensitivity Reagent Kit		PerkinElmer	CLS760672
Library quantification kit	KAPA Library Quantification Kit for Illumina Platforms		KAPA Biosystems	KK4824

Protocol Steps & Timing

2 days

	Steps	Timing	Stop & Store
	Step 1 – Probe Hybridization		
	1.1 Probe Hybridization	Overnight	
	Step 2 – Probe Ligation		
	2.1 Post Hybridization Wash	15 min	
	2.2 Probe Ligation	65 min	
	2.3 Post Ligation Wash	15 min	 4°C ≤24 h
	Step 3 – Probe Release & Extension		
	3.1 RNA Digestion & Probe Release	75 min	
	3.2 Probe Extension	20 min	 4°C ≤72 h
	3.3 Probe Elution	15 min	 -20°C ≤72 h
	Step 4 – Visium Spatial Gene Expression – FFPE Library Construction		
	4.1 Cycle Number Determination - qPCR	45 min	
	4.2 Sample Index PCR	40 min	 4°C ≤24h
	4.3 Post Sample Index PCR - Cleanup	30 min	 -20°C long-term
	4.4 Post Library Construction QC	50 min	

Stepwise Objectives

Visium Spatial Gene Expression for FFPE assays RNA levels by using probes against the whole transcriptome in intact formalin fixed paraffin embedded (FFPE) tissue sections and maps the location(s) where gene activity is occurring. Each Visium Spatial Gene Expression Slide contains Capture Areas with gene expression spots that include primers required to capture the probes. Tissue sections placed on these Capture Areas are deparaffinized, stained, and decrosslinked, as described in Deparaffinization & Staining Demonstrated Protocols – CG000409 or CG000410.


Human or mouse whole transcriptome probe panels, consisting of a pair of specific probes for each targeted gene, are then added to the tissue. These probe pairs hybridize to their gene target and are then ligated to one another. The ligation products are released from the tissue upon RNase treatment and permeabilization. The ligated probe pairs bind with spatially barcoded oligonucleotides present on the Capture Area. All the probes captured by primers on a specific spot share a common Spatial Barcode. Libraries are generated from the probes and sequenced and the Spatial Barcodes are used to associate the reads back to the tissue section images for spatial mapping of gene expression.

This document outlines the protocol for generating Visium Spatial Gene Expression – FFPE libraries from FFPE tissue sections placed on the Capture Areas of a Visium Spatial Gene Expression Slide.

Visium Slide


The Visium Spatial Gene Expression Slide has 4 Capture Areas. Each Capture Area is 6.5 x 6.5 mm and defined by a fiducial frame (fiducial frame + Capture Area is 8 x 8 mm). The Capture Area has ~5,000 gene expression spots, each spot with primers that include:

- Illumina TruSeq Read 1 (partial read 1 sequencing primer)
- 16 nt Spatial Barcode (all primers in a specific spot share the same Spatial Barcode)
- 12 nt unique molecular identifier (UMI)
- 30 nt poly(dT) sequence (captures ligation product)




Step 1 Probe Hybridization

The human or mouse whole transcriptome probe panel, consisting of a pair of specific probes for each targeted gene, is added to the deparaffinized, stained, and decrosslinked tissues. Together, probe pairs hybridize to their complementary target RNA.




Step 2 Probe Ligation

After hybridization, a ligase is added to seal the junction between the probe pairs that have hybridized to RNA, forming a ligation product.




Step 3 Probe Release & Extension

The single stranded ligation products are released from the tissue upon RNase treatment and permeabilization, and then captured on the Visium slides. Once ligation products are captured, probes are extended by the addition of UMI, Spatial Barcode and partial Read 1. This generates spatially barcoded, ligated probe products, which can then be carried forward for library preparation.



Step 4 Visium Spatial Gene Expression - FFPE Library Construction


The spatially barcoded, ligated probe products are released from the slide and harvested for qPCR to determine Sample Index PCR cycle number. The products then undergo indexing via Sample Index PCR. This, in turn, generates final library molecules that are cleaned up by SPRIselect, assessed on a bioanalyzer or a similar instrument, quantified, and then sequenced.



Step 5 Sequencing

A Visium Spatial Gene Expression – FFPE library comprises standard Illumina paired-end constructs which begin and end with P5 and P7. The 16 bp Spatial Barcode and 12 bp UMI are encoded in Read 1, while Small RNA Read 2 (Read 2S) is used to sequence the ligated probe insert.

Illumina sequencer compatibility, sample indices, library loading and pooling for sequencing are summarized in step 5.



See Appendix for Assay Scheme and Library Sequence

Tips & Best Practices



Icons



Tips & Best Practices section includes additional guidance



Signifies critical step requiring accurate execution



Troubleshooting section includes additional guidance

General Reagent Handling


- Fully thaw and thoroughly mix reagents before use.
- Use a pH meter to adjust pH as necessary during buffer preparation.

Pipette Calibration

- Follow manufacturer's calibration and maintenance schedules.
- Pipette accuracy is particularly important when using SPRIsellect reagents.

Visium Slides

- Visium slides include 4 Capture Areas (6.5 x 6.5 mm), each with ~5,000 unique gene expression spots.
- Each gene expression spot includes primers with a unique Spatial Barcode (see [Stepwise Objectives](#) for additional information).
- The active surface of the slide is defined by a readable label that includes the serial number.
- The tissue sections are always placed on the active surface of the Capture Areas. For more information, consult the Visium Spatial Gene Expression for FFPE – Tissue Preparation Guide (Demonstrated Protocol CG000408).



Slide Storage

- Always store slides in a cool, dry environment.
- Store unused slides in original packaging and keep sealed. DO NOT remove desiccant. If necessary, place the sealed container in a secondary container, such as a resealable bag.
- After tissue placement, store the slides at **room temperature** in a low moisture environment such as a desiccator.

Slide Handling


- Always wear gloves when handling slides.
- Ensure that the active surface of a slide faces up and is never touched. The orientation of the label on the slide defines the active surface.
- The tissue sections should always be on the active surface of the slide. DO NOT touch the tissue sections on the slide.
- Minimize exposure of the slides to sources of particles and fibers.
- Keep the slide flat on the bench when adding reagents to the active surface.
- Ensure that no absorbent surface is in contact with the reagents on the slide during incubation.

Active Surface with Tissue Sections



Visium Cassette

- The Visium Cassette encases the slide and creates leakproof wells for adding reagents.
- Place the slides in the Visium Cassette only when specified.
- The Visium Cassette includes a removable Visium Gasket.
- An Insert Clip and four tabs at the back of the Visium Cassette are used for holding the slide in the cassette, as shown.
- The removable Visium Gasket corresponds to the Capture Areas on the slides.
- The Visium Cassette may be assembled using the Slide Alignment Tool or manually. Instructions for both are provided in the following section.
- See [Visium Cassette Assembly & Removal](#) instructions for details.
- Ensure that the back of the Visium Cassette is facing the user prior to assembly. The active surface of the slide with tissue sections will face down such that the slide label is no longer readable.
- Practice assembly with a plain glass slide (75 x 25 x 1 mm).
- Applying excessive force to the slide may cause the slide to break.




Visium Cassette Assembly



Exercise caution when handling slide edges to prevent injury.


Position Visium Cassette along alignment tool ridges



Visium Cassette secured on alignment tool




Push Insert Clip along the ridge & press Visium Cassette down




Position Visium Gasket to align with Visium Cassette cutouts



Insert long edge of slide under tabs 1 & 2; ensure slide is flush



Press slide down until it is flush with the Visium Gasket and under tabs 3 & 4




Remove Visium Cassette while pressing slide against the Visium Gasket



Slides in images are representative.

Visium Cassette Removal

Position Visium Cassette along alignment tool ridges




Push Insert Clip along the ridge & press down



Visium Cassette sits securely on alignment tool



Lift slide at Visium Cassette groove



Slides in images are representative.


Manual Visium Cassette Assembly & Removal

Assembly

- Remove the Visium Gasket from the Visium Cassette and re-insert the Visium Gasket, ensuring that the Visium Gasket and Visium Cassette cutouts are aligned.
- Align the label on top of the slide to the top of the Visium Cassette, as shown.
- Insert the slide under tabs 1 and 2. Ensure that the long edge of the slide is flush with the side of the Visium Cassette.
- Press the insert clip **very firmly** by applying even force on the lower part of the insert clip.
- Place a finger in between tab 3 and the top of the cassette, and one finger between tab 4 and the bottom of the cassette. Press down on the slide evenly until the slide is under each tab and release the insert clip.

Removal


- Press the insert clip very firmly to release the slide from the cassette.
- Lift slide at Visium Cassette groove between tabs 3 and 4 until the slide can be removed.



Reagent Addition to Wells




- Place the assembled slide in the Visium Cassette flat on a clean work surface.
- Dispense reagents along the side of the wells without touching the tissue sections and without introducing bubbles.
- Always cover the tissue section completely when adding reagents to the well. A gentle tap may help spread the reagent more evenly.
- Ensure that no bubbles are introduced in the process.



Reagent Removal from Wells

- Place the assembled slide in the Visium Cassette flat on a clean work surface.
- Slightly tilt the Visium Cassette while removing the reagent.
- Place the pipette tip to the bottom edge of the wells.
- Remove reagents along the side of the wells without touching the tissue sections and without introducing bubbles.
- Ensure that no bubbles are introduced in the process.
- Remove all liquid from the wells in each step. To ensure complete removal, check the bottom of the well by tilting the cassette slightly. A meniscus at the bottom of the well will indicate the presence of liquid in the well.



Post Hybridization & Post Ligation Washes

- Post hybridization and post ligation washes are critical for assay performance. Failure to perform the correct number of washes can significantly reduce the fraction of targeted reads usable.
- Washing for less than the recommended time and reagent carry over during washes can also reduce the fraction of targeted reads usable.
- Remove all liquid from the well when washing, and refer to appropriate step for correct number of washes and incubation times.

Visium Slide Seal Application & Removal

To generate new or resize Visium Slide Seals, use one of the provided seals (PN-2000283/2000284) as a template to cut additional seals from MicroSeal 'B' PCR Plate Sealing Film (PN-MSB1001; listed in Additional Kits, Reagents & Equipment). Contact support@10xgenomics.com if assistance is required.


Application

- Place the Visium Cassette flat on a clean work surface.
- Remove the back of the adhesive Visium Slide Seal.
- Align the Visium Slide Seal with the surface of the Visium Cassette and apply while firmly holding the Visium Cassette with one hand.
- Press on the Visium Slide Seal to ensure uniform adhesion.

Removal

- Place the Visium Cassette flat on a clean work surface.
- Pull on the Visium Slide Seal from the edge while firmly holding the Visium Cassette. Ensure that no liquid splashes out of the wells.


Visium Slide Seal Application



Slide Incubation Guidance

Incubation at a specified temperature

- Position a Thermocycler Adaptor on a thermal cycler that is set at the incubation temperature.
- Ensure that the Thermocycler Adaptor is in contact with the thermal cycler surface uniformly.
- When incubating a slide encased in a Visium Cassette, place the assembled unit on the Thermocycler Adaptor with the wells facing up. The Visium Cassette should always be sealed when on the Thermocycler Adaptor.



Incubation at room temperature

- Place the slide/Visium Cassette on a flat, clean, non-absorbent work surface.
- Ensure that no absorbent surface is in contact with the reagents on the slide during incubation.

Tissue Detachment on Visium Slides



- Monitor section adhesion on the Visium slides throughout the workflow.
- Tissue detachment during the workflow can impact performance.

10x Magnetic Separator




- Offers two positions of the magnets (high and low) relative to a tube, depending on its orientation. Flip the magnetic separator over to switch between high (magnet•**High**) or low (magnet•**Low**) positions.
- If using MicroAmp 8-Tube Strips, use the high position (magnet•**High**) only throughout the protocol.



Magnetic Bead Cleanup Steps

- During magnetic bead based cleanup steps that specify waiting “until the solution clears”, visually confirm clearing of solution before proceeding to the next step. See adjacent panel for an example.
- The time needed for the solution to clear may vary based on specific step, reagents, volume of reagents etc.



SPRIselect Cleanup & Size Selection


- After aspirating the desired volume of SPRIselect reagent, examine the pipette tips before dispensing to ensure the correct volume is transferred.
- Pipette mix thoroughly as insufficient mixing of sample and SPRIselect reagent will lead to inconsistent results.
- Use fresh preparations of 80% Ethanol.

Sample Indices (i5/i7) in Sample Index PCR

- Choose the appropriate sample index sets to ensure that no sample indices overlap in a multiplexed sequencing run.
- Each well in the Dual Index Plate TS Set A contains a unique i7 and a unique i5 oligonucleotide.
- To avoid the risk of cross-contamination, use each index once.

Sample Preparation, Deparaffinization & Staining Guidelines

Workflow Overview



Sample
Preparation
Guidelines

Proper tissue handling and preparation techniques preserve the morphological quality of the tissue sections and the integrity of mRNA transcripts. Maintaining high quality RNA is critical to assay performance.

Listed below are some key considerations for preparing samples that are compatible with the Visium Spatial Gene Expression for FFPE.



Consult the Visium Spatial Gene Expression for FFPE – Tissue Preparation Guide for complete information (Demonstrated Protocol CG000408), including Tips & Best Practices for tissue sectioning and section placement.


Key Considerations

Slide Handling (before sectioning)

- ☐ Store unused slides in original packaging and keep sealed. DO NOT remove desiccant. If necessary, store original packaging in a secondary container such as a resealable bag.

FFPE Tissue Sectioning & Section Placement

- ☐ Assess RNA quality of the FFPE tissue block.
- ☐ Section the FFPE tissue block using a microtome and place sections on the Visium Spatial slides using a water bath.
- ☐ Place tissue sections on the Capture Area within the fiducial frame on the slide.



Slide Handling (after sectioning)

- ☐ Store the slides containing FFPE sections for up to 2 weeks in a desiccator.

Deparaffinization, Staining & Decrosslinking Guidelines



FFPE tissue sections should be deparaffinized, stained, imaged, and decrosslinked before proceeding with Visium Spatial Gene Expression for FFPE. Consult Demonstrated Protocols (available on the 10x Genomics Support website) for details.

DO NOT proceed with User Guide steps without performing appropriate deparaffinization, staining, imaging, and decrosslinking for the tissue sections on the appropriate Visium slide.

Deparaffinization, H&E Staining, Imaging, & Decrosslinking

Consult Visium Spatial Gene Expression for FFPE – Deparaffinization, H&E Staining, Imaging & Decrosslinking (Demonstrated Protocol CG000409). In this protocol, Visium slides containing FFPE tissue sections are first deparaffinized and then stained with Hematoxylin and Eosin (H&E). The stained slides are then coverslipped and imaged. After the coverslip is removed, a decrosslinking step is performed. Once the slides are decrosslinked, proceed directly to the User Guide.



Deparaffinization, Decrosslinking, IF Staining & Imaging

Consult Visium Spatial Gene Expression for FFPE – Deparaffinization, Decrosslinking, IF Staining & Imaging (Demonstrated Protocol CG000410). In this protocol, Visium slides containing FFPE tissue sections are first deparaffinized and then decrosslinked. The slides are then stained with fluorescently labeled antibodies, coverslipped, and imaged. Once the immunostained tissue sections are imaged and the coverslip is removed, proceed directly to the User Guide.



Step 1

Probe Hybridization

1.1 Probe Hybridization



Get Started

1.0 Probe Hybridization

Item					10x PN	Preparation & Handling	Storage
Equilibrate to room temperature							
☐		FFPE Hyb Buffer			2000423	Thaw at room temperature. If precipitate persists, heat at 37°C until dissolved. Avoid vortexing to prevent bubble formation. Keep the buffer at room temperature after thawing. Store at –20°C when not in use.	–20°C
Place on ice							
☐		Perm Enzyme B			3000602/ 3000553	Pipette mix, centrifuge briefly. Maintain on ice until ready to use. Dilute 200X by adding 1 µl Perm Enzyme B in 199 µl Buffer EB.	–20°C
Probes for human samples							
☐		Human WT Probes – RHS			2000453/ 2000449	Thaw on ice. Vortex and centrifuge briefly.	–20°C
☐		Human WT Probes – LHS			2000454/ 2000450	Thaw on ice. Vortex and centrifuge briefly.	–20°C
Probes for mouse samples							
☐		Mouse WT Probes – RHS			2000457/ 2000455	Thaw on ice. Vortex and centrifuge briefly.	–20°C
☐		Mouse WT Probes – LHS			2000458/ 2000456	Thaw on ice. Vortex and centrifuge briefly.	–20°C
Obtain							
☐		Nuclease-free Water			-	-	Ambient
☐		Visium Cassette & Gasket Assembly			2000282/ 2000281	See Tips & Best Practices	Ambient
☐		Visium Slide Seals			2000284/ 2000283	See Tips & Best Practices	Ambient
☐		Buffer EB			-	-	Ambient
☐		10% Tween-20			-	-	Ambient
☐		10X PBS			-	-	Ambient

1.1 Probe Hybridization



Before starting this protocol, ensure that slide has been appropriately deparaffinized, stained, imaged, and decrosslinked. Consult Visium Spatial Gene Expression for FFPE – Deparaffinization, H&E Staining, Imaging & Decrosslinking (Demonstrated Protocol CG000409) and Visium Spatial Gene Expression for FFPE – Deparaffinization, Decrosslinking, IF Staining & Imaging (Demonstrated Protocol CG000410).




During reagent removal steps, ensure that **all the liquid is removed** from the wells. See Tips & Best Practices for guidance on Reagent Removal.

- a. Prepare Pre-hybridization Mix shortly before using and keep at **room temperature**. Pipette mix 10x and centrifuge briefly.

Pre-hybridization Mix <i>Add reagents in the order listed. Maintain at room temperature.</i>	10x PN	1X (μ l)	4X+ 10% (μ l)	8X + 10% (μ l)
Nuclease-free Water	-	89.0	391.6	783.2
10X PBS	-	10.0	44	88
Diluted Perm Enzyme B Dilute Perm Enzyme B 200X in Buffer EB before using. DO NOT use concentrated stock directly.	3000602/ 3000553	0.5	2.2	4.4
10% Tween-20	-	0.5	2.2	4.4
Total	-	100.0	440.0	880.0

- b. Retrieve the Visium Cassette containing H&E stained or IF stained sections and remove the Visium Slide Seal.
- c. Using a pipette, remove all buffer from the well corners. For H&E stained slide, remove all TE buffer. For IF stained slide, remove all PBS.
- d. Add **100 μ l** Pre-hybridization Mix along the side of the wells to uniformly cover the tissue sections, without introducing bubbles.
- e. Apply Visium Slide Seal on the cassette and incubate for **15 min** at **room temperature**.
- f. Prepare a thermal cycler with the following incubation protocol and start the program.



Lid Temperature	Reaction Volume	Run Time
50°C	100 µl	-
Step	Temperature	Time
Pre-equilibrate	50°C	Hold
Hybridization	50°C	Overnight (16 - 24 h)
Post Hybridization Wash	50°C	Hold

- g. Prepare Probe Hybridization Mix shortly before using and keep at room temperature. Pipette mix 10x and centrifuge briefly.

Probe Hybridization Mix <i>Add reagents in the order listed.</i> <i>Maintain at room temperature.</i>				
	10x PN	1X (µl)	4X + 10% (µl)	8X + 10% (µl)
Nuclease-free Water	-	10.0	44.0	88.0
FFPE Hyb Buffer	2000423	70.0	308.0	616.0
Human WT Probes –RHS Or Mouse WT Probes – RHS	2000453/ 2000449 Or 2000457/ 2000455	10.0	44.0	88.0
Human WT Probes – LHS Or Mouse WT Probes – LHS	2000454/ 2000450 Or 2000458/ 2000456	10.0	44.0	88.0
Total	-	100.0	440.0	880.0

- h. Remove all Pre-hybridization Mix from the wells.
- i. Add **100 µl** room temperature Probe Hybridization Mix to each well.
- j. Apply a **new** Visium Slide Seal on the cassette and place on the Thermocycler Adaptor on the pre-heated thermal cycler. Close the thermal cycler lid.
- k. Skip Pre-equilibrate step to initiate Hybridization.



Step 2

Probe Ligation

- 2.1** Post Hybridization Wash
- 2.2** Probe Ligation
- 2.3** Post Ligation Wash



Get Started

2.0 Probe Ligation

	Item	10x PN	Preparation & Handling	Storage
Equilibrate to room temperature				
☐	FFPE Post-Hyb Wash Buffer	2000424	Thaw at room temperature. If precipitate persists, heat at 37°C until dissolved. Vortex and centrifuge briefly.	-20°C
☐ 	2X Probe Ligation Buffer	2000446/ 2000445	Thaw at room temperature. Vortex and centrifuge briefly.	-20°C
☐	Post Ligation Wash Buffer	2000420/ 2000419	Thaw at room temperature. If precipitate persists, heat at 37°C until dissolved. Vortex and centrifuge briefly. The tube is filled to the top. Pipette carefully.	-20°C
Place on ice				
☐ 	Probe Ligation Enzyme	2000426/ 2000425	Thaw on ice. Centrifuge briefly.	-20°C
Obtain				
☐	Nuclease-free Water	-	-	Ambient
☐	20X SSC Buffer	-	-	Ambient

2.1 Post Hybridization Wash

- a. Pre-heat FFPE Post-Hyb Wash Buffer (**495 µl/per sample**) to **50°C**.
- b. Prepare 2X SSC Buffer.

SSC Buffer					
Add reagents in the order listed. Maintain at room temperature.					
	Stock	Final	1X (µl)	4X + 10% (µl)	8X + 10% (µl)
SSC	20X	2X	120.0	528.0	1056.0
Nuclease-free Water	-	-	1080.0	4752.0	9504.0
Total	-		1200.0*	5280.0*	10560.0*

**This volume of 2X SSC Buffer is sufficient for washes in all the subsequent steps.*



- c. Remove the Visium Cassette from the Thermocycler Adaptor and place on a flat, clean work surface.
- d. Remove the Visium Slide Seal and using a pipette, remove all Probe Hybridization Mix from the wells.
- e. **Immediately** add **150 µl pre-heated** FFPE Post-Hyb Wash Buffer to each well. Avoid well drying or cooling to room temperature. Removal and addition of buffers should be done quickly.
- f. Apply Visium Slide Seal on the cassette and place on the Thermocycler Adaptor on the pre-heated thermal cycler. Close the thermal cycler lid.
- g. Skip the Hybridization step and initiate Post Hybridization Wash. Incubate in the thermal cycler at **50°C** for **5 min**.
- h. Remove the Visium Cassette from the Thermocycler Adaptor and place on a flat, clean work surface.
- i. Remove the Visium Slide Seal and using a pipette, remove all FFPE Post-Hyb Wash Buffer from the wells.
- j. **Repeat** e-i two more times.
- k. Add **150 µl** 2X SSC Buffer to each well.
- l. Let the cassette cool to **room temperature (~ 3 min)** before proceeding to the next step.



2.2 Probe Ligation

- a. Prepare a thermal cycler with the following incubation protocol and start the program.

Lid Temperature	Reaction Volume	Run Time
37°C (lid may be turned off if the instrument doesn't enable 37°C)	100 µl	1 h

Step	Temperature	Time
Pre-equilibrate	37°C	Hold
Ligation	37°C	01:00:00
Hold	4°C	Hold

- b. Prepare Probe Ligation Mix shortly before using. Pipette mix 10x and centrifuge briefly.

Probe Ligation Mix <i>Add reagents in the order listed. Maintain on ice.</i>	10x PN	1X (µl)	4X + 10% (µl)	8X + 10% (µl)
Nuclease-free Water	-	24.0	105.6	211.2
☐ 2X Probe Ligation Buffer	2000446/ 2000445	30.0	132.0	264.0
☐ Probe Ligation Enzyme	2000426/ 2000425	6.0	26.4	52.8
Total	-	60.0	264.0	528.0

- c. Remove all 2X SSC Buffer from all wells.
- d. Add **60 µl** Probe Ligation Mix along the side of the wells to uniformly cover the tissue sections, without introducing bubbles. Tap Visium Cassette gently to ensure uniform coverage.
- e. Apply a new Visium Slide Seal on the Visium Cassette and place on the Thermocycler Adaptor on the pre-heated thermal cycler. Close the thermal cycler lid. Discard old slide seals.
- f. Skip Pre-equilibrate step to initiate Ligation.



2.3 Post Ligation Wash



*Use room temperature Post Ligation Wash Buffer at the first wash step (step 2.3e). Use pre-heated Post Ligation Wash Buffer at the second wash step (step 2.3j).

- a. Pre-heat Post Ligation Wash Buffer* (**110 µl/sample**) to **57°C**. Only **100 µl** per sample is needed.
- b. Remove the Visium Cassette from the Thermocycler Adaptor and place on a flat, clean work surface.
- c. Prepare a thermal cycler with the following incubation protocol and start the program.

Lid Temperature	Reaction Volume	Run Time
57°C	100 µl	-
Step	Temperature	Time
Incubate	57°C	Hold



- d. Remove the Visium Slide Seal and using a pipette, remove all Probe Ligation Mix from all wells.
- e. Immediately add **100 µl room temperature** Post Ligation Wash Buffer to each well. The Post Ligation Wash Buffer should be at **room temperature**. Avoid well drying.
- f. Apply Visium Slide Seal on the Visium Cassette and place on the Thermocycler Adaptor on the pre-heated thermal cycler. Close the thermal cycler lid.
- g. Incubate at **57°C** for **5 min**.
- h. Remove the Visium Cassette from the Thermocycler Adaptor and place on a flat, clean work surface.
- i. Remove the Visium Slide Seal and using a pipette, remove all Post Ligation Wash Buffer.
- j. Add **100 µl pre-heated** Post Ligation Wash Buffer* to each well.
- k. Apply Visium Slide Seal on the Visium Cassette and place on the Thermocycler Adaptor on the pre-heated thermal cycler. Close the thermal cycler lid.
- l. Incubate at **57°C** for **5 min**.
- m. Remove the Visium Cassette from the Thermocycler Adaptor and place on a flat, clean work surface.
- n. Remove the Visium Slide Seal and using a pipette, remove all Post Ligation Wash Buffer.
- o. Add **150 µl 2X SSC** Buffer prepared at step 2.1b to each well.
- p. Remove all 2X SSC buffer.
- q. Add **150 µl 2X SSC** Buffer to each well.
- r. Let the slides cool to **room temperature** and proceed to next step or apply Visium Slide Seal on the Visium Cassette and store the slides in 2X SSC Buffer at **4°C** for up to **24 h**.



Step 3

Probe Release & Extension

- 3.1** RNA Digestion & Probe Release
- 3.2** Probe Extension
- 3.3** Probe Elution

3

Get Started

3.0 Probe Release & Extension

	Item	10x PN	Preparation & Handling	Storage
	Equilibrate to room temperature			
☐	 Extension Buffer	2000409/ 2000408	Thaw at room temperature, vortex, centrifuge briefly.	-20°C
☐	 2X RNase Buffer	2000411/ 2000410	Thaw at room temperature, vortex, centrifuge briefly.	-20°C
☐	 Perm Buffer B	2000413/ 2000412	Thaw at room temperature. DO NOT vortex.	-20°C
	Place on ice			
☐	 Extension Enzyme	2000427/ 2000389	Pipette mix, centrifuge briefly. Maintain on ice until ready to use.	-20°C
☐	 Perm Enzyme B	3000602/ 3000553	Pipette mix, centrifuge briefly. Maintain on ice until ready to use.	-20°C
☐	 RNase Enzyme	3000605/ 3000593	Pipette mix, centrifuge briefly. Maintain on ice until ready to use.	-20°C
	Obtain			
☐	Nuclease-free Water	-		Ambient
☐	Tris 1 M, pH 7.0 (Tris-HCl)	-	Manufacturer's recommendations.	Ambient
☐	2X SSC Buffer	-	Prepared at step 2.1b.	Ambient
☐	8 M KOH Solution	-	Manufacturer's recommendations.	Ambient
☐	Visium Slide Seals	2000284/ 2000283	See Tips & Best Practices.	Ambient

3.1 RNA Digestion & Probe Release

- a. Place a Thermocycler Adaptor in the thermal cycler. Prepare the thermal cycler with the following incubation protocol and start the program.

Lid Temperature	Reaction Volume	Run Time
37°C (lid may be turned off if the instrument doesn't enable 37°C)	100 µl	~ 70 min

Step	Temperature	Time
Pre-equilibrate	37°C	Hold
RNA Digestion	37°C	00:30:00
Hold	37°C	Hold
Permeabilization	37°C	00:40:00

- b. Prepare RNase Mix shortly before using. Vortex and centrifuge briefly.

RNase Mix <i>Maintain on ice</i>	10x PN	1X (µl)	4X + 10% (µl)	8X + 10% (µl)
Nuclease-free Water	-	33.0	145.2	290.4
● 2X RNase Buffer	2000411/ 2000410	37.5	165.0	330.0
● RNase Enzyme	3000605/ 3000593	4.5	19.8	39.6
Total	-	75.0	330.0	660.0

- c. Using a pipette, remove all 2X SSC Buffer from the wells. If the slide was stored overnight, remove the Visium Slide Seal before removing the 2X SSC Buffer.



- d. Add **75 µl** RNase Mix to each well. Gently tap the cassette to ensure uniform coverage of the Capture Area.
- e. Apply a new Visium Slide Seal on the Visium Cassette and place on the Thermocycler Adaptor on the pre-heated thermal cycler. Close the thermal cycler lid. Discard old slide seals.
- f. Skip Pre-equilibrate step to initiate RNA Digestion.

- g. Prepare Permeabilization Mix shortly before using and pipette mix 10x. DO NOT vortex.

Permeabilization Mix <i>Maintain at room temperature</i>	10x PN	1X (μl)	4X + 10% (μl)	8X + 10% (μl)
● Perm Buffer B	2000413/ 2000412	70.3	309.4	618.8
● Perm Enzyme B	3000602/ 3000553	4.7	20.6	41.2
Total	-	75.0	330.0	660.0

- h. After the RNA Digestion is complete, remove the Visium Cassette from the Thermocycler Adaptor and place on a flat, clean work surface.
- i. Remove the Visium Slide Seal and using a pipette, remove all RNase Mix from the wells.
-  j. Add **75 μl** Permeabilization Mix to each well. Gently tap the cassette to ensure uniform coverage of the Capture Area.
- k. Apply a new Visium Slide Seal on the Visium Cassette and place on the Thermocycler Adaptor on the pre-heated thermal cycler. Close the thermal cycler lid. Discard old slide seals.
- l. Skip Hold step to initiate Permeabilization.
- m. After the permeabilization is complete, remove the Visium Cassette from the Thermocycler Adaptor and place on a flat, clean work surface.
- n. Remove the Visium Slide Seal and using a pipette, remove all Permeabilization Mix from the wells.
The tissue might disintegrate during Permeabilization. This is normal and does not affect performance.
- o. Add **175 μl** 2X SSC Buffer prepared at step 2.1b to the each well.
- p. Remove all 2X SSC Buffer from the wells.
- q. **Repeat** o-p one more time.
- r. Add **175 μl** 2X SSC Buffer to the each well and proceed **immediately** to Probe Extension.

3.2 Probe Extension

- a. Prepare the thermal cycler with the following incubation protocol and start the program.

Lid Temperature	Reaction Volume	Run Time
45°C (lid may be turned off if the instrument doesn't enable 45°C)	100 µl	15 min
Step	Temperature	Time
Pre-equilibrate	45°C	Hold
Probe Extension	45°C	00:15:00
Hold	4°C	Hold

- b. Prepare Probe Extension Mix shortly before using. Vortex and centrifuge briefly.

Probe Extension Mix <i>Maintain on ice</i>	10x PN	1X (µl)	4X + 10% (µl)	8X + 10% (µl)
● Extension Buffer	2000409/ 2000408	73.5	323.4	646.8
● Extension Enzyme	2000427/ 2000389	1.5	6.6	13.2
Total		75.0	330.0	660.0

- c. Remove all 2X SSC Buffer from the wells.
- d. Add **75 µl** Probe Extension Mix to each well. Gently tap the cassette to ensure uniform coverage of the Capture Area.
- e. Apply a new Visium Slide Seal on the Visium Cassette and place on the Thermocycler Adaptor on the pre-heated thermal cycler. Close the thermal cycler lid. Discard old slide seals.
- f. Skip Pre-equilibrate step to initiate Probe Extension.
- g. After the Probe Extension is complete, **immediately** proceed to next step or store slides at **4°C** for up to **72 h**. DO NOT remove the Visium Slide Seal during storage.




3.3 Probe Elution

- a. Prepare 0.08 M KOH Mix. Vortex and centrifuge briefly.

KOH Mix <i>Maintain at room temperature</i>	Stock	Final	1X (μ l)	4X + 10% (μ l)	8X + 10% (μ l)
KOH	8 M	0.08 M	0.4	1.8	3.5
Nuclease-free Water	-	-	39.6	174.2	348.5
Total	-		40.0	176.0	352.0

- b. Remove the Visium Cassette from the Thermocycler Adaptor and place on a flat, clean work surface, after the Probe Extension is complete.
- c. Remove the Visium Slide Seal and using a pipette, remove all Probe Extension Mix from the wells.
- d. Add **100 μ l** 2X SSC Buffer prepared at step 2.1b to each well.
- e. Remove all 2X SSC Buffer from the wells.
- f. Add **40 μ l** 0.08 M KOH Mix to each well. Gently tap the cassette to ensure uniform coverage of the Capture Area.
- g. Incubate at room temperature for **10 min.**
- h.  Transfer all solution containing the ligation product to an 8-tube strip. DO NOT leave behind any solution in the wells. The solution might contain tissue pieces. Transfer all the solution even if there is tissue.
See Tips & Best Practices for reagent removal instructions.
- i. Add **5 μ l** 1 M Tris-HCl pH 7.0 to the solution in the 8-tube strip.



Vortex, centrifuge briefly, and place on ice.



- j. Proceed to next step or store at **-20°C** for up to **72 h.**

Step 4

Visium Spatial Gene Expression – FFPE Library Construction

- 4.1** Cycle Number Determination – qPCR
- 4.2** Sample Index PCR
- 4.3** Post Sample Index PCR Cleanup – SPRIselect
- 4.4** Post Library Construction QC



Get Started

4.0

Visium Spatial Gene Expression – FFPE Library Construction

	Item	10x PN	Preparation & Handling	Storage
Equilibrate to room temperature				
☐	Dual Index Plate TS Set A	3000511	Thaw at room temperature, vortex, and centrifuge briefly.	–20°C
☐ 	TS Primer Mix A	2000447	Thaw at room temperature, vortex, and centrifuge briefly.	–20°C
☐	Beckman Coulter SPRIselect Reagent	-	Manufacturer's recommendations.	-
☐	Agilent TapeStation Screen Tape and Reagents <i>If used for QC</i>	-	Manufacturer's recommendations.	-
☐	Agilent Bioanalyzer High Sensitivity kit <i>If used for QC</i>	-	Manufacturer's recommendations.	-
Place on ice				
☐ 	Amp Mix	2000047/ 2000113	Vortex, centrifuge briefly.	–20°C
☐	KAPA SYBR FAST qPCR Master Mix	-	Manufacturer's recommendations.	-
Obtain				
☐	Nuclease-free Water	-	-	Ambient
☐	Qiagen Buffer EB	-	Manufacturer's recommendations.	Ambient
☐	80% Ethanol	-	Prepare fresh.	Ambient
☐	10x Magnetic Separator	230003	See Tips & Best Practices.	Ambient

4.1

Cycle Number Determination – qPCR


- a. Prepare qPCR Mix on ice. Vortex and centrifuge briefly.

qPCR Mix <i>Add reagents in the order listed. Maintain on ice.</i>	Stock	Final	1X (μl)	5X* + 10% (μl)	9X* + 10% (μl)
*Includes 1 negative control					
Nuclease-free Water	-	-	4.0	22.0	39.6
KAPA SYBR FAST qPCR Master Mix <i>Minimize light exposure</i>	2X	1X	5.0	27.5	49.5
TS Primer Mix A (PN-2000447)	-	-	1.0	5.5	9.9
Total			10.0	55.0	99.0

- b. Add **9 μl** qPCR Mix to each well in a qPCR plate (a well for negative control may be included).
- c. Transfer **1 μl** sample to the qPCR plate well containing the qPCR Mix. Pipette mix, centrifuge briefly. If using a negative control, add **1 μl** nuclease-free water to the corresponding well. Briefly centrifuge.
- d. Prepare a qPCR system with the following protocol, place the plate on the thermal cycler, and start the program.

Lid Temperature	Reaction Volume	Run Time
105°C	10 μl	35 min
Step	Temperature	Time
1	98°C	00:03:00
2	98°C	00:00:05
3	63°C	00:00:30
Read signal		
4	Go to step 2, 24x (total 25 cycles)	

- e. Record the Cq Value for each sample. The threshold for determining the Cq Value should be set along the exponential phase of the amplification plot, at ~25% of the peak fluorescence value.



4.2 Sample Index PCR



- a. Choose the appropriate sample index sets to ensure that no sample indices overlap in a multiplexed sequencing run. Record the 10x Sample Index name (PN-1000251/PN-3000511 Dual Index Kit/Plate TS Set A well ID) used.
- b. Add **50 µl** Amp Mix (PN-2000047 or 2000131) to **~45 µl** sample.
- c. Add **5 µl** of an individual **Dual Index TS Set A** to each well and record the well ID used. Pipette mix 5x (pipette set to 90 µl). Centrifuge briefly.
- d. Incubate in a thermal cycler with the following protocol.

Lid Temperature	Reaction Volume	Run Time
105°C	100 µl	~25-40 min
Step	Temperature	Time
1	98°C	00:01:00
2	98°C	00:00:15
3	63°C	00:00:20
4	72°C	00:00:30
5	Go to Step 2, Use the Cq+2 Value as the total # of cycles. See table below for total # of cycle examples	
6	72°C	00:01:00
7	4°C	Hold



Contact
support@10xgenomics.com
if Cq value is >20 cycles.

Example: Cycle number examples determined based on rounding the Cq Value

Cq Value from qPCR	Total Cycles (Cq+2)
12.2	14
13.5	16
19.7	22



- e. Store at **4°C** for up to **24 h** or proceed to the next step.

4.3


Post Sample Index PCR Cleanup – SPRIselect

- a. Vortex to resuspend the SPRIselect reagent. Add **85 µl** SPRIselect Reagent (**0.85X**) to each sample. Pipette mix 15x (pipette set to 180 µl).
- b. Incubate **5 min** at **room temperature**.
- c. Place on the magnet•**High** until the solution clears.
- d. Remove the supernatant.
- e. With the tube still in the magnet, add **200 µl** 80% ethanol to the pellet. Wait **30 sec**.
- f. Remove the ethanol.
- g. **Repeat** steps e and f for a total of 2 washes.
- h. Centrifuge briefly. Place on the magnet•**Low**. Remove remaining ethanol. Air dry for **2 min**. DO NOT exceed 2 min as this will decrease elution efficiency.
- i. Remove from the magnet. Add **25.5 µl** Buffer EB. Pipette mix 15x.
- j. Incubate **2 min** at **room temperature**.
- k. Place on the magnet•**Low** until the solution clears.
- l. Transfer **25 µl** to a new tube strip.
- m. Store at **-20°C** for **long-term** storage.

STOP

4.4 Post Library Construction QC

- a. Run **1 µl** of sample (1:5 dilution) on an Agilent Bioanalyzer High Sensitivity chip.



- b. Determine the average fragment size from the Bioanalyzer trace. This will be used as the insert size for library quantification.

Alternate QC Method:

- Agilent TapeStation
- LabChip

See Appendix for representative traces


[See Appendix for Post Library Construction Quantification](#)

Sequencing

5

Sequencing Libraries

Visium Spatial Gene Expression – FFPE libraries comprise standard Illumina paired-end constructs which begin with P5 and end with P7. 16 bp Spatial Barcodes are encoded at the start of TruSeq Read 1, while i7 and i5 sample index sequences are incorporated as the index read. TruSeq Read 1 and Small RNA Read 2 (Read 2S) are standard Illumina sequencing primer sites used in paired-end sequencing. TruSeq Read 1 is used to sequence 16 bp Spatial Barcode and 12 bp UMI. Small RNA Read 2 (Read 2S) is used to sequence the Ligated Probe Insert. Sequencing these libraries produces a standard Illumina BCL data output folder.



Sequencing Depth

Sequencing Depth/spot

Minimum 25,000 read pairs per tissue covered spot on Capture Area

Sequencing Depth/sample


See example calculation below

Example:

Sequencing Depth for a Sample

- Estimate the approximate Capture Area (%) covered by the tissue section.
- Calculate total sequencing depth = (Coverage Area x total spots on the Capture Area) x 25,000 read pairs/spot
- Example calculation for 60% coverage: $(0.60 \times 5,000 \text{ total spots}) \times 25,000 \text{ read pairs/spot} = 75 \text{ million total read pairs for that sample}$

Estimated Coverage Area (%) Examples



Sequencing Type & Run Parameters

Use the sequencing run type and parameters indicated.

Dual Index Library

Paired-end, dual indexed sequencing

Read 1: 28 cycles
i7 Index: 10 cycles
i5 Index: 10 cycles
Read 2S: 50 cycles*

**Visium Spatial Gene Expression – FFPE libraries may be pooled with Visium Spatial Gene Expression libraries generated from fresh frozen samples. In that case, use 90 cycles for Read 2S. If pooling the two different library types, Visium Gene Expression - FFPE libraries should not be more than 40% of the pool.*

Illumina Sequencer Compatibility

The compatibility of the listed sequencers has been verified by 10x Genomics. Some variation in assay performance is expected based on sequencer choice. For more information about performance variation, visit the 10x Genomics Support website.

- MiSeq
- NextSeq 500/550
- NextSeq 2000
- NovaSeq
- iSeq

Sample Indices

Each well of the Dual Index Kit TS Set A (PN-1000251) contains a mix of one unique i7 and one unique i5 sample index. If multiple samples are pooled in a sequence lane, the sample index name (i.e. the Dual Index TS Set A plate well ID, SI-TS) is needed in the sample sheet used for generating FASTQs with “spaceranger mkfastq”. Samples utilizing the same sample index should not be pooled together or run on the same flow cell lane, as this would not enable correct sample demultiplexing.

Library Loading

Once quantified and normalized, the Visium Spatial Gene Expression – FFPE libraries should be denatured and diluted as recommended for Illumina sequencing platforms. Refer to Illumina documentation for denaturing and diluting libraries. Refer to the 10x Genomics Support website, for more information.

Instrument	Loading Concentration (pM)	PhiX (%)
MiSeq	11	1
NextSeq 500/550	1.8	1
NextSeq 2000	650	1
NovaSeq	150**/300	1
iSeq	150	1

** Use 150 pM loading concentration for Illumina XP workflow.

Library Pooling





Pooling Visium Spatial Gene Expression – FFPE Libraries

The Visium Spatial Gene Expression – FFPE libraries may be pooled for sequencing, taking into account the differences in tissue covered spot on a Capture Area and per-spot read depth requirements between each library. Samples utilizing the same sample index should not be pooled together, or run on the same flow cell lane, as this would not enable correct sample demultiplexing.

Troubleshooting




6

STEP	NOTES
Tissue Placement – Impact on UMI Count	Fiducials are obstructed H&E Stain  UMI count  Fiducial obstruction may result in image analysis failure. Placement must be correct before the workflow begins. If necessary, software will prompt users to manually align tissue images during analysis.
Bubbles during Coverslipping	Tissue Plot with Tissue Alignment  Tissue Plot with Spots Colored by Clustering  A bubble could be generated during coverslipping. Software may identify it as tissue and a cluster may be associated with it. In that case, perform manual alignment and identification of the tissue.
Bubbles during Coverslipping	H&E Stain  UMI Count  A bubble could be generated during coverslipping. If the bubble is on the tissue, blackening of the tissue could occur. However, this does not diminish sensitivity and spatial resolution, and the data derived from the blackened region can still be analyzed.


STEP	NOTES
------	-------

Uneven Tissue Staining – Impact on UMI Count



Ensure that staining reagents are applied to the tissue uniformly and adequate washes are performed. A gentle tap may help spread the reagent uniformly. Uneven staining does not diminish sensitivity and spatial resolution, and the data derived from the unevenly stained tissue portions can still be analyzed.

Incorrect Staining Protocol – Impact on UMI Count




Ensure the correct staining protocol is followed. If the staining protocol recommended in Demonstrated Protocol Methanol Fixation, H&E Staining & Imaging for Visium Spatial Protocols (CG000160) is followed, lower quality images will be obtained. However, incorrect staining does not diminish sensitivity and spatial resolution, and the data derived from the unevenly stained tissue portions can still be analyzed.

STEP	NOTES
------	-------

Flat Line in BioAnalyzer Library Trace

Failure to neutralize the KOH after probe elution from the slide, will result in a normal qPCR output but no peak will be visible in the BioAnalyzer trace.



Number of Washes

Post hybridization and post ligation washes are critical for assay performance. Failure to perform the correct number of washes can significantly reduce the fraction of targeted reads usable (see table below). A similar effect is observed when washing for less than the recommended 5 min, or when reagent is carried over during the washes. Remove all liquid from the well when washing, and refer to User Guide for correct number of washes and incubation times.

Wash	Number of Washes	Fraction Targeted Reads Usable (Mean)
Post Hybridization Wash	1	0.2905
	2	0.4125
	3	0.7895
Post Ligation Wash	1	0.6925
	2	0.7475

Tissue Detachment

Tissue detachment can result in a loss of gene expression complexity and spatiality in Visium Spatial Gene Expression – FFPE libraries. If tissue detachment is observed during the workflow, contact support@10xgenomics.com.

Appendix

Post Library Construction Quantification

Agilent TapeStation Traces

LabChip Traces

Assay Scheme and Sequences



Post Library Construction Quantification

- a. Thaw KAPA Library Quantification Kit for Illumina Platforms.
- b. Dilute **2 µl** sample with deionized water to appropriate dilutions that fall within the linear detection range of the KAPA Library Quantification Kit for Illumina Platforms. (For more accurate quantification, make the dilution(s) in duplicate).
- c. Make enough Quantification Master Mix for the DNA dilutions per sample and the DNA Standards (plus 10% excess) using the guidance for 1 reaction volume below.

Quantification Master Mix	1X (µl)
SYBR Fast Master Mix + Primer	12
Water	4
Total	16

- d. Dispense **16 µl** Quantification Master Mix for sample dilutions and DNA Standards into a 96 well PCR plate.
- e. Add **4 µl** sample dilutions and **4 µl** DNA Standards to appropriate wells. Centrifuge briefly.
- f. Incubate in a thermal cycler with the following protocol.

Step	Temperature	Run Time
1	95°C	00:03:00
2	95°C	00:00:05
3	67°C Read Signal 	00:00:30
4	Go to Step 2, 29X (Total 30 cycles)	

- g. Follow the manufacturer's recommendations for qPCR-based quantification. For library quantification for sequencer clustering, determine the concentration based on insert size derived from the Bioanalyzer/TapeStation trace.


Agilent TapeStation Traces

Agilent TapeStation High Sensitivity D5000 ScreenTape was used. Protocol steps correspond to the Visium Spatial Gene Expression for FFPE User Guide (CG000407).

Protocol Step 4.4 – Post Library Construction QC

Representative Trace

Run 2 μ l diluted sample (1:5 dilution) mixed with 2 μ l loading buffer.




LabChip Traces

DNA High Sensitivity Reagent Kit was used. Protocol steps correspond to the Visium Spatial Gene Expression for FFPE User Guide (CG000407).

Protocol Step 4.4 – Post Library Construction QC


Representative Trace

Run manufacturer's recommended volume of diluted sample (1:5 dilution).




Assay Scheme


Probe Hybridization




Probe Ligation



Probe Release & Extension



Visium Spatial Gene Expression – FFPE Library Construction




Sequences

Slide Primers

5'-CTACACGACGCTCTCCGATCT-N16-N12-TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT-VN-3'



Visium Spatial Gene Expression – FFPE Library



5'-AATGATACGGCGACCGAGATCTACAC-N10-ACACTCTTTCCCTACACGACGCTCTCCGATCT-N16-N12-TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT-VN-Ligated_Probe_Insert-TGGAAATCTCGGGTGCCAAAGAACTCCAGTCAC-N10-ATCTCGTATGCGGTCTCTGCTTG-3'
3'-TTACTATGCCCGCTGGTGGCTCTAGATGTG-N10-TGTGAGAAAGGATGTCTGCGAGAGGCTAGA-N16-N12-AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAABN-Ligated_Probe_Insert-ACCTTAAGAGCCACGGTCTCTGAGGTCAAGTG-N10-TAGAGCATACGGCAGAGACGAAC-5'

CERTIFICATE OF SERVICE

I, Brian E. Farnan, hereby certify that on November 23, 2022, a copy of NanoString Technologies, Inc.'s Initial Infringement Contentions was served on the following as indicated:

Via E-Mail

Karen Jacobs
Cameron P. Clark
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street
P.O. Box 1347
Wilmington, DE 19899
kjacobs@morrisnichols.com
cclark@morrisnichols.com

Attorneys for Plaintiff 10x Genomics, Inc.

Via E-Mail

Kenneth L. Dorsney
Cortlan S. Hitch
MORRIS JAMES LLP
500 Delaware Ave., Suite 1500
Wilmington, DE 19801-1494
kdorsney@morrisjames.com
chitch@morrisjames.com

*Attorneys for Plaintiff President and Fellows
of Harvard College*

Via E-Mail

Matthew Powers
Paul Ehrlich
Stefani Smith
Robert Gerrity
Li Shen
Samantha Jameson
Kiley White
TENSEGRITY LAW GROUP LLP
10x_Harvard_NSTG_Service@tensegritylawgroup.com

Attorneys for Plaintiff 10x Genomics, Inc.

Via E-Mail

Geoffrey M. Raux
Ruben J. Rodrigues
Michel J. Tuteur
Foley & Lardner LLP
graux@foley.com
rrodrigues@foley.com
mtuteur@foley.com

*Attorneys for Plaintiff President and Fellows
of Harvard College*

/s/ Brian E. Farnan

Brian E. Farnan (Bar No. 4089)